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Highlights 
• Model organisms highlight mechanisms, protein functions and relevant pathways  
• A range of model organisms with various attributes enable in vivo 
experimentation 
• Therapeutic testing for NCLs relies on a range of suitable disease models  
 
Abstract 
The NCLs (neuronal ceroid lipofuscinosis) are forms of neurodegenerative disease 
that affect people of all ages and ethnicities but are most prevalent in children. 
Commonly known as Batten disease, this debilitating neurological disorder is 
comprised of 13 different subtypes that are categorized based on the particular gene 
that is mutated (CLN1-8, CLN10-14). The pathological mechanisms underlying the 
NCLs are not well understood due to our poor understanding of the functions of NCL 
proteins. Only one specific treatment (enzyme replacement therapy) is approved, 
which is for the treating the brain in CLN2 disease. Hence there remains a desperate 
need for further research into disease-modifying treatments. In this review, we present 
and evaluate the genes, proteins and studies performed in the social amoeba, 
nematode, fruit fly, zebrafish, mouse and large animals pertinent to NCL. In 
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particular, we highlight the use of multicellular model organisms to study NCL 
protein function, pathology and pathomechanisms. Their use in testing novel 
therapeutic approaches is also presented. With this information, we highlight how 
future research in these systems may be able to provide new insight into NCL 
proteinF functions in human cells and aid in the development of new therapies.  
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Rakeb syndrome; MO, morpholino oligonucleotide; MRI, magnetic resonance 
imaging; NCL, Neuronal Ceroid Lipofuscinosis; NHP, non-human primates; REMI, 
restriction enzyme-mediated integration; RNAi, RNA interference; UPS-ubiquitin 
proteasome system; US FDA, United States Food and Drug Administration; WGS, 
whole genome sequencing. 
 
1. Introduction 
Neuronal Ceroid Lipofuscinosis is a group of fatal neurodegenerative diseases that are 
characterised by lysosomal storage of ceroid lipofuscin. Each disease is designated 
CLN followed by a number that refers to a gene. Recessive mutation in one of those 
genes causes a specific type of NCL, for example mutations in the CLN3 gene cause 
CLN3 disease. Each form of NCL has a characteristic age of onset and speed of 
progression, as well as specific storage material and appearance under electron 
microscopy. Although the central nervous system is predominantly affected, 
pathology is seen in peripheral tissues as well[1, 2]. Currently, one approved 
treatment exists for CLN2 disease – an enzyme replacement therapy infused directly 
into the brain [3].  A few gene therapies and small molecule treatments are in clinical 
trials. These are reviewed elsewhere [4, 5]. Given that the NCLs are likely to end up 
affecting other parts of the body even if the brain or retina is successfully treated, 
there is still a huge need develop further treatments for this debilitating and 
devastating disease.  Animals are required for drug testing and large animal disease 
models are particularly useful for examining penetration of treatments as their brains 
are nearly human size.  Multicellular and animal models can also shed a light on 
pathological processes and the function of CLN proteins for which the function is 
unknown, with such information leading to potential drug target identification.  
The use of multicellular models and live animals in NCL research is crucial. Using 
live animals enables researchers to investigate the effects of single gene loss on whole 
tissues and organisms. Multi-cellular organisms are also needed for investigating 
pathology, treatment efficacy, tissue-specific toxicity and immunological reactions, as 
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well as determining the relevance of the blood-brain barrier, and how a treatment is 
metabolised. If experimental results are the same across several model organisms, this 
indicates that the researchers have identified a conserved feature (rather than a 




The experimental use of animals protected by legislation must be sufficiently justified 
by results from experiments using cells or animals that are not protected by 
legislation. These include invertebrates and embryonic vertebrates, and this review 
highlights these ethical issues and demonstrates the relative uses of each organism at 
relevant stages of development. 
Traditional drug discovery methods start either by identifying a target in cellular 
models and then identifying compounds that modulate that target (target-based 
screening), or by identifying compounds that ameliorate a phenotype (phenotypic 
screening) [6]. In both cases, many thousands of compounds may be screened. Target-
based screening requires the knowledge of a target thought to be centrally involved in 
the disease, but, due to a lack of understanding of nearly all forms of NCL, targets 
have not been identified. Indeed, although the function of some NCL proteins are 
known (e.g. lysosomal enzymes such as Protein palmitoyl thioesterase 1 (PPT1), Tri-
peptidyl peptidase 1 (TPP1) and Cathepsin D (CTSD)), the function of many other 
NCL proteins remains elusive, hampering efforts to identify targets.  To perform 
phenotypic screening, an assay is used that is thought to be relevant to the disease or 
the function of the protein, but this can be hard to judge when little is known about the 
disease and the screening is limited by being carried out in cellular models. For NCL, 
phenotypic screening has included assays for apoptosis, for example [7]. Once a set of 
compounds has been identified, animals are then used to verify which compounds 
improve the disease in the animal and, unfortunately, many compounds fail at this 
point. Of those compounds that do show improvement in the animal model, several 
will fail at clinical trial because the result (efficacy or toxicity) in the animal was not 
representative of humans [8]. It has been suggested that employing animal models 
such as the social amoeba, nematodes, fruit flies, or zebrafish earlier in the phenotypic 
screening process, the use of multiple animal models, and the use of phenotypes that 
are representative of clinical signs in patients will contribute to reduce the numbers of 
failures at clinical trial [9, 10]. However, it is unlikely that the numbers of compounds 
that can be screened using animal models would ever be as great as when using cells. 
A further issue is that it is difficult to identify the target of the lead compound. This is 
often required before approval of a new drug is granted but can be waived for rare 
diseases where a treatment is not yet available. 
Another route to treatment is the replacement of a protein known to be missing, for 
example by gene therapy or enzyme replacement therapy. This could be considered a 
target-based approach. In this case, cellular models, invertebrates and non-mammalian 
vertebrates are usually bypassed and the therapy is tested first in a mammalian model, 
usually starting with a mouse model as they are the cheapest and easiest to work with. 
However, the physiology and pharmacodynamics of larger animals are more likely to 
approximate the human condition. Therefore, it is usual to also test these therapies on 
larger animals such as dogs or sheep before clinical trials in patients. 
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In this review, we first provide a brief discussion on each of the model systems that 
will be presented in the review and why they are useful for NCL research (Section 2). 
In the sections that follow (Sections 3-15), we discuss each of the NCL subtypes in 
turn. For each subtype, we present details on the model systems that have been used 
to study that particular subtype of the disease, and highlight the recent advances 
made, both fundamental and applied, using those systems. In the final section (Section 
16), we provide concluding remarks on the future of NCL research using model 
systems.   
 
2. Animal models: characteristics and ethical considerations 
2.1 Large animals and veterinary species 
Large animal models of NCL are a critical in understanding disease pathogenesis and 
testing disease modifying agents.  NCLs have been identified in dogs, cats, sheep, 
cattle, horses and most recently a monkey, however many of these are isolated 
apparently single cases reported in veterinary journals and not always with confirmed 
genetic diagnosis.  Of those that have been established as research colonies, the dog 
and sheep models are the best studied and will form the major focus for large animal 
discussion in this review, especially work described since the last Biochimica et 
Biophysica Acta - Molecular Basis of Disease review [11].  
In terms of understanding biology, pathogenesis and developing treatment strategies, 
each model system has key advantages and disadvantages. The large animal models 
replicate more of the clinical features of the human conditions and have gyrencephalic 
brains (highly folded cortices with gyri and sulci) more similar to humans. However, 
these models are generally more expensive to keep, restricted to certain facilities with 
housing capacity and limited to seasonality for collection of tissues/breeding. The 
longer lifespan and development of disease in many models also makes these more 
challenging models, though together with small animals and cellular systems provide 
a key component in the NCL research network. 
Historically, sporadic cases of NCL in large animals was identified by veterinary 
pathologists [12, 13]. Characteristic clinical signs of NCL were confirmed by 
biopsy/pathology for autofluorescent storage material and by electron microscopy to 
classify membrane structure for a preliminary definition of probable subtype. Since 
the elucidation of NCL genes, most large animal models can be identified by 
genotype. This diagnosis is still problematic in some species with incomplete genome 
coverage, however in dogs, exome and / or whole genome sequencing (WGS) 
analysis allows most forms to be distinguished. The genetically characterised forms of 
NCL in large animal models are shown in Table 1. Those that have been recently 
identified and / or established as research colonies are discussed further in relevant 
gene-associated subsections. 
Genetic modification technologies have been instrumental for the development of 
animal models, especially in mice. The technology has been slower to develop in 
large animals, though is possible [14, 15]. Several new large animal models, including 
pig models of CLN2 (J. Weimer, Sanford Research, SD, personal communication) 
and CLN3 disease [16] and a sheep model of CLN1 disease [17], are currently being 
developed. These advances will, importantly, allow the generation of  animal models 
expressing allele -specific mutations identified in patient populations, especially for 
those forms that differ dramatically in phenotype depending on underlying genotype.  
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Pre-clinical testing in large animal models is often required prior to clinical trial 
approval, at least to show safety and tolerability of any gene/drug therapy. At 
minimum these therapies require testing in non-human primates (NHP), most often in 
“wildtype’ species as, other than for CLN7 [18] no NHP models of other NCLs 
currently exist. These will be discussed in more detail where they have been used in 
specific preclinical studies. 
 
2.2 Rodents 
Rodents are probably the most commonly used animal model for studying human 
neurological diseases, among which mouse models are the most popular and 
economical option. The mouse and human genomes share around 85% identity, and a 
large number of proteins are evolutionally conserved between the mouse and human 
both in structures and functions. For monogenetic diseases, genetically modified 
mouse models provide a powerful tool for both studying human disease pathogenesis 
and testing potential therapeutic strategies. In particular, as mice have been employed 
in neuroscience research for a long time, a variety of mouse-based research tools, 
methods and databases have been well established and widely employed for 
neurobiological and behavioural studies.  
Almost all types of NCL have available mouse models with corresponding gene 
alterations, except for CLN14 disease (Table 2). Most of these models are genetically 
modified mouse lines; except for two naturally occurring mouse NCLs (mnd and 
nclf), both corresponding to human NCL subtypes [19-21] [22-25]. These mouse 
models recapitulate many typical NCL features (motor and/or visual impairments, 
neuronal lipofuscin accumulation confirmed by light and electron microscopic 
analysis, gliosis, neuro- and/or retinal degeneration, etc.)  and utilising these models 
has markedly advanced our understanding of NCL pathogenesis and also promoted 
delineating the functions of the proteins mutated in NCLs. Moreover, mouse models 
are particularly useful for investigating potential therapeutic approaches. The small 
body size/weight, ease of handling and low cost makes the mouse an ideal 
mammalian model for testing novel therapies or drugs with a decent sample size but 
not over-expenditure. However, due to dramatic differences in the lifespan, 
brain/body size and structures between the mouse and human, pre-clinical therapy 
testing with large animal models is still irreplaceable before proceeding to clinical 
trial, especially for testing long-term efficacy, safety and tolerability. Available 
murine models of all NCLs as well as corresponding use in pre-clinical studies are 
listed in Table 2. NCL research advances using mouse models will be discussed in 
detail in the following sections of this article.     
 
2.3 Zebrafish 
In the 1980s, George Streisinger (Univ. Oregon, USA) was the first researcher to 
substantially promote the use of zebrafish, Danio rerio, for genetics and 
developmental biology. Since then, publications have increased from a handful each 
year to about 5000 in 2016 (reviewed in [26]). The main driver for the uptake of this 
model organism into laboratories is that is the only vertebrate that is transparent 
during embryonic and larval stages, and can be maintained as transparent using either 
chemical or genetic tricks. Add in features such as external fertilisation and 
development, easy care, easy generation of large numbers, breeding all year round, 
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ability to breed for at least a year, and a diploid genome, and you have a powerful 
vertebrate model organism for developmental genetics. Furthermore, zebrafish 
embryos and larvae prior to free-feeding at 5 days post-fertilisation (dpf) are not 
protected species in relation to animal experimentation. As zebrafish hatch from their 
chorion at 3dpf, are swimming and have developed several behaviours, they are useful 
for motor function and behavioural studies from this age. Many zebrafish mutants 
have an earlier onset phenotype than their mammalian equivalents (e.g. zebrafish 
versus mouse and canine models of CLN2 disease [27-29]), enabling quicker results. 
Although genetic manipulation is not as simple as for invertebrate model organisms, 
many of the methods generated in Drosophila have been translated to the zebrafish. A 
variety of genetic screens have been performed using mutagens, transposons, viruses, 
antisense morpholinos, and, more recently, gene editing. Transgenics are easily 
generated and these frequently exploit the model’s transparency to label proteins, 
visualise processes or activate neurons via optogenetics in a spatio-temporal manner, 
as well as kill target cells with a laser. Transgenics are also useful for identifying 
donor and host cells after transplantation of tissue. Examples of all these methods are 
reviewed elsewhere [26].  
Zebrafish embryos and larvae readily absorb chemicals in which they are bathed and 
this provides a quick and easy delivery route for chemicals. They are just 1-2 mm in 
length so can be housed in very small wells such as in a 96 or 384 well plate, 
therefore needing only small amounts of chemical, and making chemical treatments 
relatively cheap.  These advantages have resulted in the use of zebrafish embryos are 
larvae for toxicological assessment and chemical screens, which is particularly useful 
when searching for new drugs. Although the delivery route is likely to be somewhat 
different from a final drug, and the zebrafish may not have yet developed its blood-
brain barrier (which it does at 3 dpf), this is nevertheless a powerful method in drug 
discovery (reviewed in [30]). 
As a vertebrate, the zebrafish is closer in evolutionary terms to humans than the fruit 
fly and other invertebrates, but less close than the mouse and other mammals. Indeed, 
the nervous system has a very similar plan throughout and homologous structures and 
connections can be identified, except for the lack of a cerebral cortex. However, 
zebrafish vision is cone-dominated and therefore considered to reflect the human 
situation better than the mouse [31] and this may be pertinent to NCL research. On the 
other hand, the ability of the zebrafish to regenerate tissues such as various parts of 
the retina, the spinal cord and the heart, is something many scientists are trying to 
understand to enable us to stimulate regeneration of human tissues. 
The last 15 years has seen a huge increase in the number of diseases modelled in 
zebrafish, including those affecting the nervous system. Indeed, some models are 
turning out to be very useful as the effect of drugs in zebrafish is predictive of the 
effect in humans and this has led to drugs reaching clinical trials for human 
neurological diseases such as epilepsy [32, 33] and amyotrophic lateral sclerosis 
(ALS) [34, 35]. The generation of genetic models of disease can sometimes be 
hampered by genome duplications during evolution, meaning that there are often two 
zebrafish homologs for a human gene [36]. As we do not know what functions are 
retained or altered in each homolog, we frequently have to target both to generate a 
model. Quite often, antisense morpholino oligonucleotides (MO) are injected into the 
newly fertilised embryo to knock-down the target protein during the first few days of 
life. This frequently results in NCL-like phenotypes, but great care must be taken to 
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control for off-target effects and toxicity (guidelines found in [37]).   Fortuitously, 
several large forward and reverse mutagenesis screens have resulted in mutations in 
NCL genes, and these are awaiting phenotyping to assess their suitability as disease 
models. To generate new mutations in NCL genes, gene-editing techniques are now 
predominantly used [38]. It is curious that not all loss-of-function mutations in CLN 
genes result in an NCL-like phenotype, and it remains to be seen if a compensatory 
mechanism is elicited in these mutant, but phenotypically normal, zebrafish. If this 
turns out to be the case, perhaps that compensatory mechanisms can be elicited in 
patients to provide a novel therapeutic strategy.  
To date, acceptable zebrafish models for CLN2 and CLN10 diseases exist (Table 3), 
with both of these exhibiting embryonic and larval phenotypes reminiscent of NCL to 
varying degrees. Many other mutants have not yet been researched, and details of 
these can be found on the zebrafish database ZFIN (zfin.org). This suggests that the 
zebrafish is currently being under-utilised for NCL research. 
 
2.4 Fruit fly 
The fruit fly, Drosophila melanogaster, has been used as a model to study genetics, 
developmental biology and neurobiology for more than a century. The unparalleled 
genetic tools available in Drosophila allow for more detailed manipulation of genes, 
genotypes and phenotypes than in any other laboratory model and the short generation 
times, ease of handling and absence of licencing requirements permit these tools to be 
used on a genome-wide basis [39]. Drosophila has homologues of 75% of human 
disease-causing genes [40] and the ease of manipulating these genes has made flies a 
popular choice to model human diseases. They are particularly useful for monogenic 
inherited disorders where the Drosophila gene can be mutated to mirror the human 
condition, and in gain-of-function disorders, including forms of neurodegeneration 
such as Alzheimer’s, Parkinson’s and Huntington’s diseases [41-43]. In addition, the 
Drosophila CNS has been used for many decades as a model system to understand 
aspects of neural development and function: from identifying the transcription factor 
networks that regulate neural specification; how components of the synapse function; 
to the pioneering of optogenetic tools to manipulate neural activity to map the circuits 
that control behaviour [44-46]. Despite the much smaller size and obvious anatomical 
differences between the mammalian and insect brains, many functions are 
orthologous, and the smaller size enables in vivo imaging. Like the mammalian brain, 
the fly brain is modular, with regionally-specific functions controlling complex 
behaviours, including learning and memory, movement and visual processing [47]. 
The major excitatory and inhibitory neurotransmitters used in the mammalian CNS 
are also used in the fly, along with numerous neuropeptides [48, 49]. The fly brain 
also has specialised glia with orthologous roles to mammalian glia, and a blood-brain-
barrier isolating the CNS [50]. 
Drosophila has only a subset of the human CLN disease genes: the soluble lysosomal 
enzymes, Ppt1 (CLN1), cathepsin D (Drosophila gene name = cathD) and cathepsin F 
(CG12163); the membrane proteins, Cln3, Cln7 (CG8596) and ATP13A2 (anne 
boleyn); and cysteine string protein (Csp). Unusually, cysteine string protein had been 
studied extensively for its role in synaptic function prior to its identification of as a 
NCL disease locus. Of the remainder, Ppt1 and Cln3 are perhaps the best understood 
with both gain-of-function and loss-of-function studies reported for both genes. 
Recent single cell transcriptomics studies indicate that the lysosomal enzymes are 
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widely expressed within the CNS and present in most, potentially all, neurons. In 
contrast, the Cln3 and Cln7 genes are more restricted. Both genes are expressed 
primarily in glia, with Cln3 also expressed in some neurons (see 
http://scope.aertslab.org/ for scRNA-seq data). 
 
2.5 Nematode 
Caenorhabditis elegans (C. elegans) is a small, non-parasitic nematode worm. In the 
wild, it feeds on bacteria in decomposing vegetable matter. In the laboratory, it is 
normally maintained on agar plates with bacteria (usually E. coli) added as a food 
source. Over 99% of worms are self-fertilising hermaphrodites, and a single 
hermaphrodite can produce around 300 eggs using its own sperm [51]. The ability of 
a single worm to generate large numbers of genetically identical offspring is very 
useful, as it enables stable maintenance of mutant strains without the need for mating. 
Nevertheless, rare males can be isolated and mated with hermaphrodites, which 
increases fecundity to around 1000 eggs per hermaphrodite. This ability to mate with 
males is important, as it enables genetic crossing for applications such as construction 
of double mutant strains. Development from an egg through four larval stages to the 
approximately 1 mm-long adult usually takes around 3 days at 20°C [52]. However, if 
food is scarce, worms arrest their development and enter an alternative larval form 
known as dauer. These dauer larvae can survive without eating for several months, 
resuming normal development once food becomes available. This is useful in the 
laboratory, as worms on agar plates can be left unattended for many weeks without 
fear of losing an important strain. Furthermore, C. elegans can withstand freezing and 
thawing, permitting the long-term maintenance of worms as frozen stocks. Adult 
lifespan is usually around 3 weeks under well-fed conditions, which facilitates the 
analysis of age-related phenotypes, such as adult onset forms of NCL.  
These characteristics help to explain why C. elegans was adopted by Sydney Brenner 
as a new model organism in the 1960s. However, Brenner’s main reason was that the 
extreme simplicity of C. elegans made it feasible to determine the complete structure 
of the nervous system [52]. Indeed, the C. elegans nervous system comprises just 302 
neurons, out of a total of 959 cells in the adult hermaphrodite; whereas Drosophila 
contains around 100,000 neurons. C. elegans is unique among animals in that the 
position and developmental fate of every cell from zygote to adult is fully 
documented [53, 54], as are all of the synaptic connections made by its 302 neurons 
[55]. The animal is naturally transparent, and individual neurons can be visualised in 
freely moving animals via cell-specific promoters driving fluorescent reporter 
proteins such as GFP. This is particularly useful for studies of neurodegenerative 
diseases such as NCL, as it enables direct assessment of neuronal degeneration and 
death in vivo by visualising neuronal fluorescence as a readout [56]. Thousands of 
hermaphrodites can be stably maintained on agar plates without the need for mating, 
making C. elegans well suited to high-throughput genetic screens. Indeed, the unique 
ability to perform genome-wide knock down of protein expression via RNA 
interference (RNAi) simply by feeding the worms transformed versions of their 
standard laboratory food source, E. coli, is particularly powerful in this regard [57]. 
One drawback for the study of NCLs is that worm neurons are relatively resistant to 
RNAi compared to other tissues, but this issue can be addressed by using strains that 
are generally hypersensitive to RNAi [58] or exhibit enhanced RNAi specifically in 
neurons [59]. Finally, the extreme simplicity of the worm nervous system means there 
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are no ethical issues about animal suffering to be considered. Taken together, these 
various features of C. elegans explain why it has become one of the main model 
organisms used worldwide despite being developed comparatively recently. 
 
2.6 Social amoeba 
The social amoeba Dictyostelium discoideum has emerged as an excellent model 
organism for studying a variety of neurological disorders (e.g. Alzheimer’s, 
Parkinson’s and Huntington’s Disease, epilepsy, etc) , including the NCLs [60-65]. Its 
34 MB haploid genome, which is contained on six chromosomes, encodes 
approximately 12,500 proteins, is fully sequenced and annotated, and contains 
homologs of 11 of the 13 human NCL genes [62, 66, 67]. One of the main advantages 
of using Dictyostelium as a biomedical model system is its 24-hour life cycle that is 
comprised of distinct unicellular and multicellular phases [68] (Fig. 1). This allows 
researchers to study the effects of gene-deficiency on conserved cellular and 
developmental processes (e.g., cell movement, cell differentiation, intracellular 
trafficking, autophagy, etc.) within the context of a whole organism [68]. In the 
presence of nutrients, Dictyostelium grows as single cells, dividing by mitosis and 
obtaining nutrients by endocytosis [68] (Fig. 1). Nutrient depletion prompts a 24-hour 
developmental program that consists of a sequence of well-defined events. Upon 
starvation, cells secrete cAMP, which acts as a chemoattractant causing cells to 
aggregate into multicellular mounds. Mounds then form motile slugs (or 
pseudoplasmodia) composed of primarily two cells types, pre-stalk and pre-spore. 
Terminal differentiation of these cells results in the formation of a fruiting body 
comprised of a mass of dormant spores that are supported above the surface by a 
slender stalk. In nature, the spores are dispersed and when conditions are favourable 
(e.g., food source available), they germinate to form single cells, thus re-starting the 
life cycle.  
Dictyostelium cells grow rapidly in the lab at room temperature and can be cultured 
inexpensively in liquid medium (8-12 hour doubling time) or on agar plates with 
bacteria (3-4 hour doubling time) [69]. Due to their fast doubling time, cells can be 
harvested in large numbers and used for a variety of cellular, developmental, and 
biochemical assays [68]. Dictyostelium is amenable to genetic manipulation (RNA 
interference, restriction enzyme-mediated integration mutagenesis, site-directed 
mutagenesis, multiple gene knockout via homologous recombination or 
CRISPR/Cas9-mediated targeting) and a variety of expression constructs have been 
generated to facilitate studies on protein localization and function [70-76]. In addition, 
several proteomic analyses have been performed in Dictyostelium to reveal proteins 
that are secreted during development, proteins that are contained within the 
extracellular matrix (ECM), and proteins that localize to the macropinocytic pathway 
[77-80]. These analyses show that 10 of the 11 NCL protein homologs are present in 
the macropinocytic pathway and 5 of the 11 homologs are secreted [77, 78, 80]. 
Importantly, these results are consistent with results from mammalian models of 
Batten disease that link the NCL proteins to a shared or convergent biological 
pathway [81]. Finally, there are many resources available to Dictyostelium researchers 
including dictyBase (the model organism database for Dictyostelium), dictyExpress 
(web application that compiles data from over 1,000 Dictyostelium microarrays and 
RNA-seq experiments of wild-type and mutant cell lines), and the Dicty Stock Center 
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at Northwestern University (central repository for Dictyostelium cell lines and 
expression constructs) [66, 82, 83].   
Despite the evolutionary time gap between Dictyostelium and human, there are many 
advantages of using this organism as a model system for biomedical research. Since 
many human diseases, particularly those affecting the nervous system, share common 
cellular features such as storage body accumulation, mitochondrial dysfunction, and 
the accumulation of autophagic vacuoles, the study of Dictyostelium allows for the 
examination of these and other relevant processes in an organism with measurable 
phenotypic outcomes [60, 84]. Due to the metazoan-like behaviour of Dictyostelium 
cells, findings from this organism are highly translatable to more complex eukaryotic 
systems. Finally, the biology underlying the life cycle of Dictyostelium has been 
studied for more than 80 years, which has allowed the research community to reveal 
key components of the signal transduction pathways that regulate the growth and 
development of the organism.  
 
 
Figure 1. The life cycle of Dictyostelium discoideum. During growth, single cells 
feed on bacteria and divide by mitosis. Upon starvation, cells chemotactically 
aggregate to form multicellular mounds. Mounds then form fingers, which fall on the 
surface to generate motile slugs (also known as pseudoplasmodia). During 
culmination, terminal differentiation of pre-stalk and pre-spore cells forms fruiting 
bodies. Each fruiting body is composed of a slender stalk that supports a mass of 
dormant spores. When environmental conditions are favourable (e.g., food source 
available), the spores germinate allowing the cells to restart the life cycle. Top panel 
was previously published in [68]. Bottom panel was previously published in [85]. 
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3. CLN1 disease, caused by mutations in Palmitoyl protein thioesterase (PPT1) 
Homozygous mutations in the lysosomal enzyme Palmitoyl protein thioesterase 1 
(PPT1) cause CLN1 disease. 
 
3.1 Large animals  
To date mutations in CLN1 have been confirmed in miniature Dachshunds 
(CLN1:c.736-737insC; [86] and the Cane Corso (CLN1:c.124 +1G>A, a splice site 
mutation; [87]). Both founders exhibited symptoms around 8 months of age with 
progressive blindness, ataxia and lethargy. To our knowledge neither of these dogs 
have been established as a research colony.  
 
3.2 Rodents 
The mouse homolog of PPT1, a 306 amino acid protein encoded on chromosome 4, 
shares 85% identity with human PPT1 (CLUSTALW (2.1) Multiple Sequence 
Alignment on Ensembl (www.ensembl.org)). For both mice and rats, PPT1 is highly 
expressed in the developing brain and eyes [88-91]. Particularly, PPT1 is expressed in 
the synaptic compartments of mouse neurons [90, 92-94], indicating its potential 
involvement in synaptic development or function.  
Genetically modified mouse models with PPT1 deficiency have been developed to 
model CLN1 disease. Two Ppt1 null mouse lines were generated independently by 
disruption of either exon 9 or 4 of the Ppt1 gene [95, 96]. Characterising studies 
showed typical NCL-like pathology in various CNS regions, including neuronal 
autofluorescent storage material accumulation, astrocytosis, microgliosis and 
neurodegeneration, with changes in the cerebellum and thalamus earlier than in the 
cerebral cortex [95-99]. In the visual system, apart from pathology of the visual nuclei 
in the thalamus, Ppt1 null mice also show retinal ganglion cell and photoreceptor cell 
loss as well as immune cell infiltration into the optic nerve [98, 100, 101]. Ppt1 null 
mice exhibit phenotypes typical of CLN1 disease, including progressive motor 
abnormalities, seizures, vision loss and a markedly shortened lifespan [95, 96, 102]. 
Khaibullina et al. found the Ppt1 mouse also displayed age-dependent impairment of 
thermoregulation, which is also observed in a group of CLN1 patients [103, 104]. 
More recently, another two mouse lines modelling CLN1 disease have been generated 
by knocking in the most common CLN1 disease-causing nonsense mutation R151X, 
both of which recapitulated the phenotype and pathology hallmarks of CLN1 disease 
[105, 106]. These knock-in mice offer more options for in vivo studies of CLN1 
disease, and particularly, provide a more disease-relevant model for testing nonsense 
suppression therapies.  
Mouse models of CLN1 disease are invaluable tools for neurobiological studies 
especially at pre-symptomatic stages of the disease, which could provide important 
information on PPT1 functions and mechanisms underlying CLN1 disease. A 
proteomic analysis of the Ppt1 null mouse has revealed protein profile changes at 
different stages, and highlighted dysregulated protein trafficking and mitochondrial 
function starting pre-symptomatically, and changes of synaptic and myelin proteins at 
early-symptomatic stages [107]. It provides clues for the biological pathways initially 
affected in the disease and different aspects of PPT1 functions. Several studies using 
the Ppt1 null mouse combined with in vitro culture systems have revealed PPT1 
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functions in the lysosome, such as contribution of PPT1 on maintaining lysosomal 
degradative functions by affecting cathepsin D maturation [108] and on lysosomal 
normal acidification by promoting vacuolar ATPase assembly [109]. Moreover, given 
that PPT1 is observed in the synaptic compartments of neurons, PPT1 functions in 
synapses could be of particular importance in the CNS. Indeed, the Ppt1 mouse shows 
impaired recycling of synaptic vesicle proteins and decreased synaptic vesicle pools 
in the presynaptic terminal, which is caused by loss of the PPT1 depalmitoylating 
activity [94]. Such synaptic changes may represent a potential mechanism underlying 
CLN1 disease progression, independent of PPT1-related lysosomal dysfuctions. 
Additionally, astrocytes appear to contribute to the pathogenesis of CLN1 disease. 
Characterization of Ppt1 null mice showing astrocytosis occurring prior to neuronal 
loss and microgliosis in the thalamus, cerebellum and cerebral cortex suggests 
astrocyte alteration as an early pathological change rather than a secondary response 
to neurodegeneration [98, 99, 110]. In vitro evidence shows PPT1 deficiency in 
astrocytes results in an exacerbated reactive state that is more neurotoxic, but exact 
contribution of such changes to CLN1 disease still needs further validation in vivo 
[111].  
Full spectrum characterisation of the Ppt1 null mouse makes it a good model to test 
therapies. For CLN1 disease, various therapeutic strategies have been developed and 
studied pre-clinically in the Ppt1 null mouse models. Since PPT1 is a soluble 
lysosomal enzyme, enzyme replacement has been suggested. A recombinant PPT1 has 
been tested in the Ppt1 null mouse model [112, 113]. Chronic intravenous delivery 
from birth and short-term intrathecal delivery at 6 weeks of age (pre-symptomatic) 
both significantly delayed the behavioural phenotype development and increased the 
lifespan; however, the improvement is limited, probably due to lack of persistent high 
PPT1 activity in the CNS. NtBuHA, a non-toxic molecule crossing the blood-brain 
barrier and mimicking the thioesterase activity of PPT1, was also tested with the Ppt1 
mouse model and showed improvement of several PPT1-related lysosomal functions 
such as restoring vacuolar ATPase activity and cathepsin D activity [108, 109]. Also, 
pathology including autofluorescent storage material accumulation, neuronal loss, 
astrocytosis and motor abnormality were improved with 3 months treatment starting 
pre-symptomatically, but still, lifespan was only slightly improved [114]. Similarly, 
since the mice only received 3 months treatment, the issue of achieving long-term 
enzyme activity needs to be resolved. Moreover, gene therapy is considered as an 
attractive strategy for various NCLs. For CLN1 disease, brain-targeted gene therapy 
via recombinant AAV vectors has also been performed on the Ppt1 null mouse. Brain 
pathology and motor function impairment were significantly decreased in a few pre-
clinical studies with AAV gene therapy intracranially delivered to newborn mice 
[115-118].  Although seizure frequency and lifespan were not obviously changed in a 
study published in 2006 [116], improvement was shown in other later studies using a 
much higher dose of viral vectors [115, 118]; however, the lifespan was still much 
shorter than wild-type mice.  Combining gene therapy with systemic administration of 
either a PPT1 mimetic or an anti-inflammatory drug did not produce a large 
synergistic effect [115, 118]. Interestingly, coupled intracranial and intrathecal AAV 
gene transfer was found to rescue the pathology throughout the CNS including the 
spinal cord and largely increase the lifespan to around 19 months, suggesting the 
clinical significance of more widespread CNS treatment for CLN1 disease [119]. 
Therefore, in future, novel approaches could be further studied on CLN1 mouse 
models in order to achieve more persistent and broader distribution of PPT1 




The zebrafish has one homolog of PPT1. The surrounding synteny is preserved, as are 
the splice sites. The zebrafish gene encodes a predicted 303 amino acid protein with 
65% identity with humans (CLUSTAL W (1.81) multiple sequence alignment on 
Ensembl (www.ensembl.org)). Zebrafish Ppt1 is expected to be found in all tissues. 
The mRNA is highly expressed from fertilisation to gastrulation 
(https://www.ebi.ac.uk/gxa/home), and then at a lower level up to 5 days post 
fertilisation (dpf). Expression of the mRNA appears to be higher in the developing 
brain [120]. The protein has been reported as found in synaptosome fractions in the 
adult zebrafish central synapses, in contrast to both synaptosome and post-synaptic 
density fractions in mice [121]. To date, there are no publications showing phenotypes 
caused by mutation in zebrafish Ppt1. Two nonsense mutations do exist (Table 3), 
which could be examined for NCL-like phenotypes. 
 
3.4 Fruit fly 
CLN1 disease was the first NCL to be modelled in the fruit fly [122]. Drosophila Ppt1 
protein shares greater than 55% identity with the human protein and the gene is 
widely expressed throughout the development stages of the fly and is maintained in 
adults. Recent single cell transcriptomics indicates that Ppt1 is expressed in both 
neurons and glia in the adult CNS but expression is not detectable at high levels in all 
neurons. This is consistent with similar scRNA-seq data from human CNS cells (see 
atlas at http://scope.aertslab.org/). The Ppt1 gene lies on the X chromosome and is 
uncovered by a small deficiency, Df(1)446-20,  that deletes three genes. Male flies 
hemizygous for this deficiency or females trans-heterozygous for the deficiency and 
either of two point mutations in the Ppt1 gene accumulate autofluorescent storage 
material in lysosomes. The material differs somewhat from the classic granular 
deposits seen in CLN1 disease and instead are more laminar in nature [122]. 
Interestingly, Ppt1 deficient flies show little or no sign of neurodegeneration despite 
quite dramatically reduced lifespan [122]. 
A major advantage of using Drosophila to study aspects of human disease is the 
ability to use unbiased, genome-wide genetic screens to provide an insight into the 
cellular pathways and genes involved in the biology of the disease. This approach has 
been used to screen for modifiers of a Ppt1 overexpression phenotype in the 
developing fly eye which disrupts the regular array of ommatidia [123, 124]. The 
genes emerging from these screens pointed strongly to a role for Ppt1 outside of the 
lysosome in regulating endocytosis, confirmed by follow-up experiments that 
revealed defects in endocytosis in Ppt1 deficient cells [124]. Interactions were also 
regulating pre-synaptic development via retrograde signalling from the post-synaptic 
cell [123, 124]. These intriguing interactions led to experiments that exploited a 
second strength of Drosophila – as a model system for neurobiology – to look for 
roles of Ppt1 in neural function.  
Maintaining normal synaptic activity is highly dependent on endocytosis to retrieve 
synaptic vesicle membrane. Thus, blocking endocytosis, for instance with the 
temperature-sensitive dynamin mutation shibirets, leads to rapid paralysis when flies 
are shifted to the restrictive temperature. Flies carrying both the shibirets and loss-of-
function Ppt1 point mutations, became paralysed far more quickly than shibirets flies 
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alone suggesting endocytosis is further compromised when Ppt1 function is missing 
[125]. Synaptic vesicle transmission is also dependent on a palmitoylation cycle of 
key proteins, including SNAP, VAMP and syntaxin [126]. This suggests Ppt1, as a 
de-palmitoylating enzyme, may be involved in the regulation of synaptic 
transmission. Searching for such a role, Korey and colleagues examined synaptic 
vesicle release at the Drosophila larval neuromuscular junction, an accessible 
glutamatergic synapse that is used extensively as a model of mammalian excitatory 
synapses. In Ppt1 mutants, synaptic vesicles were released spontaneously at an 
increased rate but, importantly, the amplitude of the miniature evoked junction 
potentials (EJPs) recorded from the post-synaptic cell was unaltered [125]. The mini 
EJP amplitude is dependent on the quantal content of the vesicles and the density and 
organisation of the post-synaptic glutamate receptors and, hence, these are likely to be 
largely unaffected by loss of Ppt1 function. The overall development of the larval 
neuromuscular junction was also unaffected, suggesting Ppt1 is not required for the 
BMP-based retrograde signalling[125]. This is in contrast to mutations in other 
lysosomal storage disorder proteins, including Spinster and Trpml, where mutations 
do result in clear developmental deficits at the neuromuscular junction [127, 128]. 
Still outstanding is to identify whether the Drosophila Ppt1 is present at synapses in 
addition to its principal localisation in lysosomes. However, Ppt1 has been detected in 
synaptosomes from human brain material and co-localises with the synaptic vesicle 
protein, synaptophysin, in cultured neurons [94]. Moreover, the levels of synaptic 
vesicle-associated proteins and synaptic vesicle trafficking are altered in brain 
material from CLN1 disease patients and form Ppt1 KO mice. The Drosophila 
electrophysiology studies are consistent with these mammalian findings. Viewed 
together, these studies argue that altered neuronal physiology results directly from 
loss of Ppt1 function in the pre-synaptic compartment and that this contributes to 
CLN1 disease, potentially independently of effects on lysosomal function. 
 
3.5 Nematode 
Although mutations in PPT1 cause very severe phenotypes and death at young ages in 
humans and mammalian models, mutation or RNAi knockdown of the C. elegans 
orthologue, ppt-1, has surprisingly little effect [129, 130]. A variety of phenotypes 
have been examined, including size, morphology, fecundity, lifespan, locomotion, 
age-dependent motility, mechanosensation, autofluorescence and lipid accumulation. 
Some very mild effects on individual phenotypes were observed for specific mutant 
alleles or RNAi knockdown. For example, gk131 deletion mutants exhibited a small 
increase in locomotion and maximum lifespan, whereas ppt-1 RNAi showed a 
decreased median lifespan using an RNAi hypersensitive strain [130]. However, no 
consistency was seen across the different mutant alleles analysed, suggesting that the 
observed effects were unrelated to loss of PPT-1 function. It is unlikely that the mild 
effects reported are due to inefficient impairment of PPT-1 protein function, as the 
gk131, gk134, gk139 and gk140 alleles studied are insertion/deletion mutants that are 
predicted to produce non-functional enzymes (Table 4). Furthermore, gk139 has been 
shown experimentally to be a null allele and lysates from gk139 strains display greatly 
reduced PPT-1 enzyme activity [129]. Interestingly, electron microscopy analysis of 
gk139 mutants exhibited altered mitochondrial morphology in young worms, which 
may be related to the slight developmental and reproductive delay observed in this 
strain and the gk140 mutant [129]. Although this may be relevant to mitochondrial 
dysfunction in CLN1 disease, it is difficult to understand why the reported 
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mitochondrial abnormalities in gk131 had no effect on lifespan [129], a phenotype 
that is known to be strongly affected by mitochondrial dysfunction. One potential 
explanation for why mutation and/or RNAi knockdown of ppt-1 has such a minor 
effect in C. elegans is redundancy with another depalmitoylating enzyme. The C. 
elegans genome encodes only one other predicted palmitoylprotein thioesterase: the 
cytoplasmic enzyme, ATH-1 [130]. However, double RNAi knockdown of both ppt-1 
and ath-1 together, or performing ppt-1 RNAi in an ath-1 mutant background also 
failed to produce strong phenotypes [130]. Presumably, an additional, as-yet-unknown 
mechanism in C. elegans compensates for the loss of PPT-1 function. Identification of 
this putative redundant mechanism could have therapeutic implications, as it might 
represent an alternative drug target for CLN1 disease. Additionally, interfering with 
this compensatory mechanism in a ppt-1 mutant genetic background might then create 
the required strong phenotype where the real power of C. elegans in applications such 
as high-throughput genetic and pharmacological screens could be used to good effect. 
For the moment, however, the very mild phenotypes exhibited by worm ppt-1 mutants 
make modelling CLN1 disease in C. elegans challenging. 
 
3.6 Social amoeba 
The Dictyostelium homolog of human PPT1 is a 303 amino acid, 34 kDa protein 
(Ppt1) encoded by the ppt1 gene. Within a 273 amino acid region of similarity 
between Ppt1 and PPT1, 46% of the amino acids are conserved and 69% are positive 
matches [62]. Like human PPT1, the Dictyostelium homolog contains a signal peptide 
for secretion, indicating that it may function extracellularly [62]. Not surprisingly, 
Ppt1 has been detected in conditioned buffer from developing Dictyostelium cells 
[77]. In addition, like many of the other NCL protein homologs in Dictyostelium, Ppt1 
is present in the macropinocytic pathway [80]. The expression of ppt1 increases 
dramatically upon starvation and peaks during the early stages of multicellular 
development [83]. Expression then decreases dramatically during the mid-to-late 
stages of development when cells terminally differentiate to form fruiting bodies [83]. 
This expression profile suggests that Ppt1 may play a role in cAMP-mediated 
chemotaxis and aggregation. While a knockout mutant has not yet been generated to 
study the function of Ppt1 in Dictyostelium, previous work suggests that the protein 
may play a role in phagocytosis, which is consistent with data from mouse models 
linking the function of PPT1 to phagocyte infiltration following neuronal death [131, 
132]. 
 
4. CLN2 disease 
Homozygous mutations in the lysosomal enzyme Tri-peptidyl peptidase 1 (TPP1) 
cause CLN2 disease. 
 
4.1 Large animals  
4.1.1 CLN2 disease in the Dachshund dog 
Mutations in canine CLN2 were first reported in the miniature longhaired Dachshund 
in 2006. These dogs present with cognitive impairments at 9 months old, and ataxia 
and visual deficits by 10 months of age.  The CLN2 dog mutation (c.325delC) causes 
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a frameshift and premature stop codon. TPP1 enzyme activity is undetectable in brain 
tissues in these animals [27].  
Disease progression has since been carefully characterised, using a range of 
biomarkers and behavioural analyses. CLN2-/- dogs display clinical signs by 5 months 
of age, progressing from hindlimb impairments to ataxia, loss of menace responses at 
6.5 months, eye involvement by 8.7 months and tremor at around 9 months, with end 
stage disease by 10-11 months. Cognitive decline is apparent using T-maze testing at 
7-9 months. These data, together with pathological findings, provide the basis for 
evaluating the efficacy of several therapeutic approaches including enzyme 
replacement therapy (ERT), mesenchymal stem cell transplantation, drug therapy and 
gene therapy. 
CLN2 disease is the first NCL to be treated clinically with enzyme replacement 
therapy (ERT) [133] and much of the pre-clinical work has been done in the CLN2-/- 
dogs [134-136]), validating previous mouse work [137, 138] and safety testing in 
dogs and monkeys [136, 139]. Catheterisation of dogs at 2 months of age was 
followed 2 weeks later, and fortnightly thereafter, with infusion of recombinant 
human TPP1. Affected and wildtype dogs (n=3/group) were assigned to one of three 
doses of enzyme or vehicle. Two dogs on the highest dose had adverse events due to 
the catheter/treatment. All dogs underwent neurological and physical examinations, 
cognitive testing and magnetic resonance imaging (MRI). Development of 
neurological deficits were delayed in the higher dose groups compared to vehicle and 
cognitive function and brain volumes were preserved and survival significantly 
increased.  Human clinical trials commenced in 2013 and both the US Food and Drug 
Administration (FDA) and the European Medicines Agency (EMA) have now 
approved ceroliponase alfa (Brineura) for clinical use in CLN2 patients [133]. 
The CLN2 dogs have also provided key data in the move towards gene therapy for 
CLN2 disease. Intracerebroventricular (ICV) infusion of canine AAV2-TPP1 at 3 
months of age (pre-symptomatic) resulted in predominantly ependymal transduction 
and spread of TPP1 protein throughout the brain and spinal cord [140]. Notably, the 
original studies in mice demonstrating AAV4 was the optimal serotype for ependymal 
transduction [141] failed to replicate in the dog, suggesting translation of animal data 
needs to be carefully considered in non-human primates. In addition, 
immunosuppression using mycophenolate mofetil and cyclosporine was required to 
prevent the generation of anti-TPP1 antibodies and loss of TPP1 activity in null dogs. 
Most importantly, AAV2-TPP1 administration to pre-symptomatic dogs delayed 
disease onset and extended lifespan, however the dogs did eventually succumb to 
disease. 
Although NCLs are primarily neurological diseases, there is increasing awareness of 
peripheral pathology, which have become more apparent as the neurological deficits 
are treated and lifespan increases. In CLN2-/- dogs, general blood biomarkers of tissue 
damage including cardiac troponin, alanine aminotransferase and creatine kinase 
increase over time, even in treated dogs. Electrocardiography (ECG) parameters were 
also significantly impaired in CLN2-/- dogs and not restored by ICV AAV2-TPP1.  
The authors suggested combined peripheral and central nervous system (CNS) gene 
transfer may be required [142]. 
Alternatively, newer generation vectors that provide both systemic and CNS 
transduction from systemic administration may provide body-wide therapy. AAV9-
TPP1 has recently been given orphan drug designation from the FDA, providing a 
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fast-track to clinical trial (https://regenxbio.gcs-web.com/news-releases/news-release-
details/fda-grants-orphan-drug-designation-rgx-181-gene-therapy). 
Another key organ for treatment in most NCLs is the eye. In CLN2-/- dogs, there is 
progressive loss of electroretinogram (ERG) activity with no recordable scotopic or 
photopic activity by 12 months of age [143].  ICV injection with AAV2-TPP1 
preserved the retinal ganglion cells, however the remainder of the retina eventually 
deteriorated and there was no preservation of ERGs in the treated affected dogs. 
[144].  
An alternative treatment approach used autologous bone marrow derived 
mesenchymal stem cells as a vehicle to deliver AAV2-TPP1 to the eye. AAV2-TPP1 
transduced stem cells were transferred into the vitreous of one eye in each of three 14-
week-old dogs [145]. Treated eyes had preserved retinal structure and ERG responses 
out to 10.5 months of age (end of study).  
Combined, these studies suggest that no one treatment will be sufficient and it is 
likely that a combination approach will be required for treatment of central and 
systemic pathologies.  
Translation of preclinical gene therapy studies in the mouse model of CLN2 disease, 
required safety studies to be completed in non-human primates. African green 
monkeys were used to demonstrate appropriate transduction and spread of TPP-1 in 
the larger monkey brain and that safety and toxicity data was obtained [146]. 
 
4.2 Rodents 
The mouse homolog of TPP1, a 562 amino acid protein encoded on chromosome 7, 
shares 88% identity with human TPP1 (CLUSTALW (2.1) Multiple Sequence 
Alignment on Ensembl (www.ensembl.org)). Tpp1 is highly expressed in the 
developing mouse, especially in the regions of high neurogenesis activity [147]. The 
expression pattern of TPP1 activity during development is slightly different between 
humans and mice. In the mouse CNS there is a persistent increase of TPP1 activity 
during the infantile and juvenile developing stages, which reaches the highest level at 
adulthood; while in the human brain the adult TPP1 activity level has been reached by 
2-4 years of age, suggesting potential differences in TPP1 function in the mouse 
compared to the human [148].  
A Tpp1 knockout mouse model has been generated to model CLN2 disease [29]. The 
mouse exhibits tremors starting from 7 weeks of age followed by progressive motor 
dysfunctions and a severely shortened lifespan (3-6 months) [29]. NCL-like 
neuropathology such as autofluorescent storage material accumulation and 
astrocytosis is observed, especially in the cerebellum [29, 138]. Cerebral and 
cerebellar neurodegeneration and axonal degeneration are also observed, but the 
pathology in the mouse cerebral cortex appears to be milder than in the human 
patients. Retinal degeneration is not observed in this mouse model. Despite the 
differences between the Tpp1 knockout mouse and human CLN2 disease, it still 
recapitulates many aspects of CLN2 disease and could be a useful tool for studying 
CLN2 disease, especially for testing potential therapies. Modification of this knockout 
model generated a line expressing Tpp1 with a missense mutation R446H that resulted 
in low levels (around 6%) of TPP1 activity in the brain [149]. This mouse line shows 
that 6% of normal TPP1 activity is capable of producing dramatic improvements and 
extension of lifespan, which provides clues for the minimal TPP1 levels that should 
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be achieved to produce proper therapeutic benefits. More recently, a knock-in mouse 
model harbouring R207X, equivalent to the most common CLN2 disease nonsense 
mutation (p.R208X), has been generated, which allows for assessing antisense 
oligonucleotides and nonsense suppression therapies [150]. This knock-in model 
exhibits severely decreased Tpp1 expression and TPP1 activity in the brain and 
visceral organs. Lysosomal accumulation of mitochondrial ATP synthase subunit C 
and astrocytosis are observed in the cerebral cortex of the knock-in model. The 
knock-in mouse displays tremors and motor function impairment from 3 months of 
age and a similar lifespan to the Tpp1 knockout mouse model. 
Pre-clinical studies with potential therapies for CLN2 disease have been widely 
performed. Brain-targeted gene therapy using the AAVrh.10 vector with TPP1 was 
investigated in Tpp1 knockout mice and showed promising improvements of 
neuropathology and behavioural performance and lifespan extension [137, 151, 152]. 
Notably, time of treatment appeared to have marked impacts on the therapeutic 
outcomes; pre-symptomatic delivery of gene therapy produced significantly better 
motor function improvement and particularly extended lifespan (around 11-12 
months), with possible reasons being early intervention before disease onset and/or 
wider distribution of transgene in the developing brain [152, 153]. Systemic delivery 
of viral vectors harbouring TPP1 has also been studied. Intra-arterial AAV-TPP1 
injection accompanied by pre-injection of mannitol (a blood-brain barrier 
permeabilizer) led to widespread transgene distribution in the mouse brain, which 
provided a novel gene transfer approach for CLN2 disease and other CNS diseases 
[154]. Apart from gene therapy, enzyme replacement therapy (ERT) is another 
attractive therapeutic strategy for CLN2 disease, given the establishment of a 
recombinant human TPP1 pro-enzyme that could be endocytosed and activated in the 
lysosome [155]. CNS-targeted ERT with this recombinant TPP1 pro-enzyme showed 
improvements of neuropathology and behavioural performance with a slightly 
extended lifespan in the knockout mouse model [138, 156], which was then tested in a 
CLN2 canine model and a small group of human patients and produced significant 
treatment benefits [133, 135, 136]. Furthermore, systemic (intravenous) delivery of 
recombinant human TPP1 produced dose-dependent brain TPP1 activity increase, 
which reached 10% of the wildtype level with a 2mg-dose injection [157]. As 
discussed earlier, achievement of 6% of the normal brain TPP1 level is capable of 
producing significant therapeutic benefits; so intravenous delivery of high dose TPP1 
could be an alternative therapeutic approach for CLN2 disease, particularly 
considering that human patients receiving CNS-targeted ERT via intraventricular 
infusion show risk of serious infusion-device-related complications [133] and that 
peripheral system could also be affected by TPP1 deficiency, systemic delivery of 
TPP1 might be a more appropriate therapeutic strategy for CLN2 disease, while 
potential risk of immune-related adverse effects that could be induced by systemic 
ERT should also be investigated. Combined intravenous injection of TPP1 and 
K16ApoE (a modified ApoE peptide) to the knockout model facilitated TPP1 
distribution throughout the brain without damaging the blood-brain barrier [158]. 
However, in vitro assays revealed a dose-dependent cytotoxicity of K16ApoE, which 
should be investigated before such an approach is considered clinically. Additionally, 
a recent study showed that orally administrated gemfibrozil (a lipid lowering drug) to 
the Tpp1 knockout mouse displayed a moderate but significant improvement of the 
disease phenotype, indicating a potential alternative and more accessible option for 




The sole homolog of TPP1 in zebrafish, called Tpp1, is 582 amino acids and has 57% 
identity with its human homolog at the protein level (CLUSTAL W (1.81) multiple 
sequence alignment on Ensembl (www.ensembl.org)). The exon/intron boundaries are 
well conserved but there is no synteny here between the zebrafish and human 
chromosomes around Tpp1. mRNA expression is predominantly in the brain of the 
developing zebrafish [120] and it has been shown in the retina at 48 hpf [28].  
The zebrafish tpp1sa11 homozygous mutant was published as a model of human CLN2 
disease [28]. A further mutant, tpp1hu3587 was homozygous viable, with trans-
heterozygotes demonstrating a mild and variable phenotype. Injection of antisense 
morpholinos designed to knock-down Tpp1 produced a similar phenotype to that seen 
in tpp1sa11 homozygotes. The tpp1sa11 model has been used most as the phenotype 
progresses very fast: it is first obvious as a small eye at 48 hours post-fertilisation 
(hpf), and mortality occurs by 7 days-post-fertilisation (dpf). With a variety of 
phenotypes and pathologies relevant to various aspects of the disease, the model can 
be used to study as many aspects of the disease as needed. However, there is an 
absence of auto-fluorescence – perhaps due to the fast disease progressing - and 
electron microscopy has not yet been performed to visualise the membrane profiles. 
 This model has been used to test premature-stop codon read-through drugs, 
demonstrating those tested to have little therapeutic potential ([160] and reviewed in 
[11]). Further conference abstracts suggest that it may be a suitable model for testing 
anti-epileptics as tpp1sa11 homozygotes treated with valproic acid have reduced 
epileptiform activity and better survival than those treated with pentobarbitone [161], 
and that a novel anti-epileptic drug was found through phenotypic screening of 
several hundred compounds [162]. Finally, abrogating inflammation does not improve 
the tpp1sa11 phenotype, as shown through genetically-induced microglia ablation and 
the use of ibuprofen and prednisolone [163]. 
Altogether, the information suggests that this model has potential for finding and 
assessing new compound treatments, though it is likely that compounds would need to 
be tested on other systems to assess the likelihood that the results can be translated to 
humans. 
 
4.4 Fruit fly 
Drosophila does not have a clear homologue of the TPP1 gene. 
 
4.5 Nematode 
C. elegans does not have a clear homologue of the TPP1 gene. 
 
4.6 Social amoeba 
The Dictyostelium genome contains six genes (tpp1A, tpp1B, tpp1C, tpp1D, tpp1E, 
and tpp1F) that encode proteins sharing sequence similarity with human TPP1 [164, 
165]. Of the six genes, tpp1B is the most highly expressed during the life cycle, 
followed by tpp1F and tpp1A [83]. tpp1C, tpp1D, and tpp1E are all expressed at 
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relatively lower amounts [83]. tpp1A was the first homolog to be identified and 
characterized in Dictyostelium [164]. tpp1A encodes a 600 amino acid, 67 kDa protein 
(Tpp1A). Within  a 552 amino acid region of similarity between Tpp1A and TPP1, 
36% of the amino acids are conserved and 52% are positive matches [62]. Expression 
of tpp1A is low during growth but increases dramatically upon the onset of 
aggregation [83]. Expression peaks after 16 hours of development when the 
multicellular slug forms and then decreases dramatically during fruiting body 
formation [83]. Like human TPP1, Tpp1A localizes to the lysosome [164, 166]. Loss 
of tpp1A reduces Tpp1 activity in Dictyostelium and causes an accumulation of 
autofluorescent storage material in starved cells [164]. tpp1A-deficient cells are also 
less viable than wild-type cells and display impaired growth in autophagy-stimulating 
media suggesting that Tpp1A plays a role in regulating autophagy [164]. Importantly, 
autophagy defects have also been reported in fibroblasts obtained from CLN2 disease 
patients [167]. During the mid-to-late stages of development, loss of tpp1A causes 
cells to develop precociously and affects spore formation, suggesting that Tpp1A may 
also regulate cell differentiation [164]. While enzyme replacement therapy is 
currently being used to treat patients with CLN2 disease, alternate indirect approaches 
may also prove to be effective therapeutic options [3]. With this in mind, work in 
Dictyostelium used restriction enzyme-mediated integration- (REMI) mutagenesis to 
identify stpA (suppressor of Tpp1A) as a second site suppressor of tpp1A-deficiency 
[164]. StpA shares some similarity with oxysterol-binding proteins, which function in 
lipid metabolism and transport [168]. Intriguingly, altered lipid homeostasis has been 
linked to the NCLs [169, 170]. Thus, the discovery of a second site suppressor in 
Dictyostelium has set the stage for future work to study second site suppressors of 
loss-of-function mutations in human TPP1.  
In addition to Tpp1A, the localizations and functions of Tpp1B and Tpp1F have also 
been studied in Dictyostelium. Tpp1B is a 598 amino acid, 65 kDa protein. Within a 
589 amino acid region of similarity between Tpp1B and TPP1, 31% of the amino 
acids are conserved and 45% are positive matches. Tpp1F is a 702 amino acid, 76 
kDa protein. Within a 369 amino acid region of similarity between Tpp1F and TPP1, 
28% of the amino acids are conserved and 44% are positive matches. Unlike Tpp1A, 
both Tpp1B and Tpp1F localize to the macropinocytic pathway and are secreted 
during development [77, 78, 80]. Also, comparing the expression profiles of tpp1B 
and tpp1F with tpp1A suggests that the proteins function at different points during the 
life cycle. In contrast to tpp1A, tpp1B and tpp1F are highly expressed during growth 
[83]. Upon starvation, the expression of both genes decreases dramatically reaching 
their lowest levels after 8-12 hours of development [83]. Expression then remains low 
during the mid-to-late stages of development [83]. In contrast, tpp1A expression 
increases dramatically upon starvation, and remains high during all stages of 
multicellular development [83]. These findings indicate that Tpp1B and Tpp1F may 
be the dominant Tpp1 proteins during growth, while Tpp1A may be the dominant 
Tpp1 protein during development. Recent work has shown that Tpp1B and Tpp1F 
bind the Golgi pH regulator (GPHR), which is a transmembrane anion channel that 
acidifies compartments of the Golgi complex and regulates growth and the later stages 
of multicellular development [165, 171, 172]. This finding should fuel research in 
human models of CLN2 disease to further explore the possible functional interaction 
between TPP1 and the GPHR. In addition to the Golgi complex, Tpp1F also localizes 
to the endoplasmic reticulum (ER) and V-ATPase-positive vesicles [165]. Tpp1F has 
serine protease activity, but loss of tpp1F has no obvious effects on growth or 
development, which could be attributed to the activities of the other Tpp1 proteins in 
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Dictyostelium [165]. Unlike tpp1A and tpp1F, a tpp1B knockout mutant has not yet 
been generated. Therefore, future research that generates knockout models for the 
other tpp1 genes in Dictyostelium is highly likely to reveal their precise roles in 
regulating the growth and development of the organism.  
 
5. CLN3 disease 
Homozygous mutations in the transmembrane protein CLN3 (Battenin) cause CLN3 
disease. 
 
5.1 Large animals  
5.1.1 CLN3 disease in pigs 
No large animal models for CLN3 disease have been identified. Using gene 
technology, a pig model was reported at by the Weimer and Pearce laboratories [16] 
that will provide a powerful model for future screening of therapies, complementing 
current animal and cellular models. 
 
5.2 Rodents 
The mouse homolog of CLN3 shares 86% identity with human CLN3 (CLUSTALW 
(2.1) Multiple Sequence Alignment on Ensembl (www.ensembl.org)). CLN3 is 
ubiquitously expressed in various mouse tissues including the CNS. Within the mouse 
CNS, Cln3 is highly expressed in various brain regions at embryonic stages; however, 
from the perinatal stage Cln3 is constantly down-regulated and in the adult brain 
shows dramatically low expression levels [173, 174]. In vitro subcellular localization 
analysis suggests that CLN3 is observed in both the soma and neurites of primary 
neurons and mainly localized to late endo-lysosomal compartments [174]. CLN3Δex7/8, 
mimicking the most common CLN3 disease genetic mutant form, results in retained 
CLN3 in the ER, suggesting impaired CLN3 trafficking [174]. 
So far, there have been four CLN3 deficient mouse models generated [173, 175-178], 
which have previously been reviewed [179]. The most commonly utilised models are 
the Cln3Δex1-6 knockout mouse and the Cln3Δex7/8 knock-in mouse [176, 178]. Both 
lines reproduced many aspects of NCLs, such as locomotor abnormalities, 
memory/learning deficits, CNS storage material accumulation, gliosis and 
neurodegeneration [175, 178, 180-195]. These models provide useful tools for in vivo 
study of CLN3 functions and preclinical work of the CLN3 disease. However, 
although storage material accumulation is observed in the retina, retinal degeneration 
is found to be mild and late-onset in these mouse models [181, 186, 190, 192, 195], 
which is notable considering that visual loss and profound retinal degeneration is 
typically one of the earliest symptoms of CLN3 patients. However, retinal 
degeneration is remarkable when the CLN3 deficient mice are crossbred on a hypo-
pigmented background [175, 196], which provides an option for utilising the mouse as 
a model for study of CLN3-related retinal abnormalities and corresponding preclinical 
work. 
Recent studies employing CLN3 deficient mice showed that CLN3 deficiency led to 
pre-synaptic impairment, in several neuronal networks in the brain. 
Electrophysiological studies suggested pre-synaptic alteration in various brain regions 
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of CLN3 deficient mice, which preceded significant neuronal loss [182, 197, 198]. 
Widespread loss of synaptophysin (a pre-synaptic marker) was observed in the Cln3 
knockout mouse brain, and ultrastructural analysis revealed significantly decreased 
synaptic vesicles in the pre-synaptic terminals [197, 199]. Additionally, 
electrophysiological analysis revealed altered synaptic transmission and plasticity 
predominantly due to pre-synaptic changes [182, 197, 198]. Further study is still 
needed to address the association between synaptic abnormality, CLN3 disease 
progression and potential underlying molecular mechanisms.   
Studies of the CLN3 deficient mouse models also suggested involvement of immune 
cells in CLN3 disease progression. . In vitro studies with primary microglial cultures 
from CLN3 deficient mice suggested CLN3 deficient microglia exhibited a more pro-
inflammatory state upon neuronal lysate stimulation [200] and resulted in more 
neurotoxic effects on primary neurons [201]. Additionally, isolated peripheral antigen 
presenting cells (APCs) from the Cln3 knockout mouse displayed dramatically 
increased levels of both total and membrane CD11c, which was not changed in other 
immune cells, indicating an APC-specific alteration [202]. Furthermore, treatment 
with immunomodulatory drugs reduced microgliosis and degeneration in the retina 
and the optic nerve of CLN3 deficient mice [196, 203]. Therefore, the immune 
response is probably not just a secondary response to other pathology, but likely 
contributes to the CLN3 disease progression and could be a potential therapeutic 
target.  
As an attractive therapeutic strategy for NCLs, gene therapy has also been studied in 
CLN3 deficient mice. Intracranial administration of AAVrh10 vectors harbouring 
CLN3 into newborn Cln3Δex7/8 mice produced improvements in neuronal lysosomal 
storage material accumulation and astrocytosis, but the effect on microgliosis or 
neurodegeneration was very limited at 16-18 months of age when transgene 
expression was still widely detected in the mouse brain [204]. Lack of microgliosis 
improvement may be caused by low microglial transduction. This study thus may 
provide additional evidence for the potential influences of microglial CLN3 
deficiency. In another study, young Cln3Δex7/8 mice received intravenous injection of 
scAAV9 vectors with CLN3 and displayed improvements of both motor abnormality 
and brain pathology including lysosomal storage material accumulation, astrocytosis 
and microgliosis at 5 months after treatment [205]. Particularly, the importance of 
promoter selection is highlighted in this study, as shown by significant improvement 
produced only in the mice with the viral vector employing the neuron-targeted 
promoter MeCP2 [205]. However, long-term therapeutic effects were not assessed in 
this study, which could be one of the reasons for the efficacy differences revealed by 
these two studies. In summary, although in one study neuronal CLN3 correction with 
gene transfer appears to be sufficient to provide phenotypic and pathologic 
improvements, long-term assessment after treatment is necessary for fully evaluating 
its therapeutic effects. Because CLN3 is a lysosomal membrane protein rather than 
secreted, CLN3 deficiency would only be rescued in the cells and regions transduced 
by viral vectors and no cross-correction would occur. In future, modifications of 
current gene transfer approaches may be needed for treating CLN3 disease.  
Other therapeutic strategies have also been tested using the CLN3 mouse models. 
Cln3 is expressed in brain endothelial cells [173] and blood-brain barrier damage is 
suggested in CLN3 disease [206, 207]. In particular, CLN3 deficiency is found to 
result in impaired membrane microdomain protein trafficking in  CLN3-deficient 
brain endothelial cells, which provides more evidence and suggests a potential 
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mechanism for the blood-brain barrier damage [206]. Recently, the same research 
group employed carbenoxolone, a gap junction inhibitor, to investigate its effect on 
CLN3-associated endothelial cell deficits and brain pathology [169]. They showed 
that the endothelial cell deficit was rescued and the brain autofluorescence 
accumulation was largely reduced. Another approach aimed to restore cAMP levels, 
which are reduced in various brain regions of the Cln3Δex7/8 mouse [208]. 
Phosphodiesterase-4 inhibitors, inhibiting the degradative activity of 
Phosphodiesterase-4 on cAMP, were also tested for their therapeutic effects for CLN3 
disease [208]. Cln3Δex7/8 mice receiving 6-month treatment showed restored cAMP 
levels in the brain and significant improvements in behavioural deficits and brain 
pathology such as lysosomal storage material accumulation and gliosis [208].  A 
study also suggested trehalose as a potential therapy for CLN3 disease [209]. They 
found that trehalose administration to the Cln3Δex7/8 mouse induced upregulation of 
autophagy/lysosomal genes by activating TFEB and improved brain pathology of the 
Cln3Δex7/8 mouse including autofluorescent storage material accumulation, gliosis and 
brain atrophy, and slightly increased the lifespan. These studies provide more 
potential options that could be considered as CLN3 disease therapies.  
 
5.3 Zebrafish 
The sole zebrafish homolog of human CLN3 is 446 amino acids long and has 48% 
identify at protein level (CLUSTAL W (1.81) multiple sequence alignment on 
Ensembl (www.ensembl.org)). No synteny is seen between the zebrafish Cln3 and 
human CLN3 loci. Expression of mRNA in the developing embryo has been 
described [210]. cln3 mRNA is maternally deposited, zygotic expression is 
ubiquitous, but then becomes stronger in the brain. 
There is one strain available with a nonsense mutation in cln3 (Table 3) but the 
phenotype has not yet been described. There were also three additional alleles 
reported at NCL2018, but these do not appear to have any phenotypes: they are adult 
viable and fertile, have normal locomotion and circadian rhythm, and normal 
electroretinograms [211]. It remains to be seen whether the Cln3 protein has been 
successfully knocked down.  
Cln3 has been effectively knocked-down by antisense morpholino [210], 
demonstrating a phenotype similar to that seen in the zebrafish tpp1sa11 homozygotes 
and morphants. Phenotypes were obvious at 24 hpf, and by 4 dpf cln3 morphants have 
a smaller retina, midbrain and hindbrain, the fourth ventricle is dilated, the heart is 
elongated and erythrocytes are not pigmented. Axon tracts are disrupted, GFAP is 
increased, proliferation is reduced and cell death increases. Furthermore, lysosomes 
are enlarged and subunit c of mitochondrial ATPase levels is increased within 
lysosomes. Mitochondria seem to have reduced membrane potential when assayed 
with Mitotracker Red. Activity is increased at 30 hpf, perhaps indicating 
hyperactivity, but the escape response and swimming ability is impaired by 4 dpf. It 
appears, through electroencephalography, that cln3 morphants are experiencing 
seizures at 4 dpf and this correlates with the earlier hyperactivity. Epileptic zebrafish 
often travel further when seizing [212], but when a 4dpf cln3 morphant is not able to 
swim, their seizures cannot be detected by the distance they travel. 
On the surface, it seems that the lack of phenotype caused by mutation calls into 
doubt the specificity of the morphant phenotype. The lack of phenotype found by 
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others using morpholinos against cln3 [213] also suggests we remain cautious when 
interpreting results.  
 
Figure 2. Zebrafish injected with antisense morpholinos against cln3 exhibit seizures. 
Reproduced under the terms of the Creative Commons Attribution License from 
[210]. 
 
5.4 Fruit fly 
The Drosophila Cln3 protein shares a predicted topology with the human protein and 
is 43% identical. Initial studies of Cln3 used an overexpression strategy to generate 
gain-of-function phenotypes in the adult wing and eye that could be used for genome-
wide screens to identify interaction pathways and genes [214]. Subsequently, a Cln3 
mutant was generated by the imprecise excision of a transposable element within the 
Cln3 locus that deletes the N-terminal half of the locus, including the first third of the 
coding sequence [215]. 
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Overexpression of Cln3 in the developing wing led to a notching phenotype typical of 
classical mutations affecting Notch signalling and likely due to effects on vesicle 
trafficking. Cln3 was also seen to interact strongly with the JNK pathway that is a 
central regulator of stress signalling. In the eye, overexpression of Cln3 led to a 
glazing phenotype that could be blocked by increasing oxidative stress scavenging 
[214]. Taken together, the gain-of-function screens pointed to a role for Cln3 in the 
responses to stress signalling and this was confirmed by examining the loss-of-
function Cln3 mutant. Cln3 mutant flies are hypersensitive to oxidative stress and 
have reduced lifespan, as are primary neurons cultured from Cln3 deficient mice and 
CLN3 disease patient fibroblasts [215]. 
The neuromuscular junction (NMJ) of the late-stage Drosophila larva is a widely used 
model system to study the development and function of excitatory glutamatergic 
synapses and has provided insight into the neural functions of genes mutated in 
neurodegenerative disorders [216]. The NMJ is reduced in size in Cln3 mutant larvae 
and when Cln3 expression is knocked-down by RNAi expressed selectively in the 
neurons. Potentially, this phenotype is underpinned by a reduced activation of the 
JNK pathway in the mutants [128].  
The endogenous Cln3 protein has proven difficult to detect in mammalian tissues due 
to low expression levels and non-specific antisera. This has left researchers reliant on 
a nuclear -galactosidase reporter to detect where and when Cln3 is expressed during 
development in the mouse [173] and overexpression of tagged forms of Cln3 have 
generally been used to study its sub-cellular localisation. Tuxworth and co-workers 
used recombineering to generate a Drosophila YFP-Cln3 knock-in that would be 
expressed at endogenous levels and under the control of the endogenous regulatory 
regions. Interestingly, this reporter demonstrated a low level and very restricted 
pattern of expression in the CNS. Cln3 is expressed predominantly in glia that form 
the blood brain barrier and in these cells there is a prominent localisation of the Cln3 
protein at the plasma membrane [217]. Single cell transcriptomics of the fly CNS 
support these findings and provides an explanation for the absence of autofluorescent 
storage material accumulating in neurons in Cln3 mutant flies (Tuxworth, 
unpublished). However, cln3 must also be expressed in glutamatergic neurons, 
including motor neurons – albeit at very low levels – since knockdown of expression 
specifically in these cells leads to synaptic phenotypes [128]. 
One organ where cln3 is strongly expressed in the fly is the Malpighian tubule, the 
insect organ concerned with solute transport and water regulation. In this regard, the 
Malpighian tubule is orthologous to the mammalian kidney so it is probably not a 
coincidence that Cln3 is also highly expressed in the mouse kidney inner medulla 
where it is required for transport of potassium into the urine [218]. Somewhat 
unexpectedly, the Drosophila knock-in revealed that the large majority of YFP-Cln3 
protein was present at the apical domain in Malpighian tubules, abutting the lumen of 
the one cell-thick tubes. This was confirmed with a specific antibody capable of 
detecting the endogenous Cln3 protein [217]. While CLN3 is clearly lysosomal in 
cultured cells, potentially it has additional localisations in polarised epithelia. 
 
5.5 Nematode 
The C. elegans genome encodes three CLN3 homologues: cln-3.1, cln-3.2 and cln-3.3 
[219, 220]. Deletion of cln-3.1 resulted in a small but significant reduction in lifespan, 
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while cln-3.2 deletion mutants exhibited a 6% decrease in the number of eggs laid per 
hermaphrodite [221], but otherwise the three single cln-3 mutant worm strains 
appeared normal. In order to investigate whether the lack of strong phenotypes was 
due to redundancy, double and triple mutant strains were created [221]. Lifespan of 
the triple cln-3 mutant was shorter than the single cln-3.1 mutant, consistent with this 
idea; but the minor fecundity defect was no greater in the triple mutant than cln-3.2 
deletion mutants, suggesting that this phenotype is specific to cln-3.2. However, cln-3 
triple mutants exhibited normal movement and behaviour and no neuronal defects 
were observed. Similarly, there were no detectable changes in lipid accumulation or 
autofluorescence; and no signs of altered lysosome morphology or abundance when 
comparing cln-3 triple mutant and wildtype worms [221]; although a recent study has 
reported a 10% increase in mitochondrial abundance in the terminal bulb of the 
pharynx [222]. To investigate the tissue specificity of cln-3 expression in C. elegans, 
the putative promoters of each gene were fused to GFP and injected into worms. 
Based on the observed fluorescence signals, it can be concluded that cln-3.1 
expression is enriched in the intestine, cln-3.2 in the hypodermis and cln-3.3 in 
specific muscle cell types and the hypodermis [221]. The lack of observed GFP 
fluorescence in neuronal cells does not rule out the possibility that CLN-3 is 
expressed physiologically in neurons, but presumably this would be at relatively low 
levels compared to other tissues. Taken together, the lack of NCL-related phenotypes 
in the cln-3 triple mutants and the lack of observable cln-3 gene expression in neurons 
suggest that C. elegans is not the best organism for modelling CLN3 disease. 
Nevertheless, a recent study used the triple cln-3 mutant strain to test for therapeutic 
effects of several different calcium channel blockers, observing that flunarizine could 
ameliorate the lifespan and mitochondrial phenotypes [222].   
 
5.6 Social amoeba 
The Dictyostelium homolog of human CLN3 is a 421 amino acid, 47 kDa 
transmembrane protein (Cln3) encoded by the cln3 gene. Within a 429 amino acid 
region of similarity between Cln3 and CLN3, 27% of the amino acids are conserved 
and 45% are positive matches [62]. cln3 is expressed at low levels during growth and 
the first 4 hours of development [83]. At the onset of aggregation, the expression of 
cln3 increases dramatically reaching its highest level after 12 hours of development 
[83]. Expression then remains high during slug and fruiting body formation [83]. In 
growth and starved conditions, Cln3 localizes predominantly to the contractile 
vacuole (CV) system, and to a lesser extent, the Golgi complex and compartments of 
the endocytic pathway [78, 223, 224]. Loss of cln3 has pleiotropic effects during the 
Dictyostelium life cycle. During growth, cln3-deficiency increases cell proliferation, 
alters cytokinesis, increases endo-lysosomal pH, and causes defects in osmoregulation 
[223, 225, 226]. During the early stages of multicellular development, cln3- cells 
accumulate autofluorescent storage material and display impaired adhesion (cell-
substrate and cell-cell) and altered protein secretion, which delays aggregation [78, 
224, 226]. Loss of cln3 also alters nitric oxide homeostasis and causes cells to develop 
precociously [223, 226]. Finally, cln3-deficiency phenotypes in Dictyostelium can be 
suppressed by treating cells with the calcium chelator EGTA, which is consistent with 
aberrant calcium homeostasis reported in a mouse model of CLN3 disease [223, 224, 
227]. Together, this work revealed previously undiscovered CLN3-dependent 
processes (e.g., protein secretion), as well as cln3-deficiency phenotypes that align 
with those observed in other genetic models of CLN3 disease (e.g., osmoregulation) 
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[147, 201, 206, 218, 228-232]. These data therefore provide strong evidence that the 
molecular function of CLN3 is conserved from Dictyostelium to human. 
As discussed above, loss of cln3 alters protein secretion in Dictyostelium [78]. During 
growth, cln3-deficiency affects the secretion and cleavage of proliferation repressors, 
which may help to explain the enhanced proliferation of cln3- cells [223]. When 
starved, loss of cln3 alters the expression and secretion of cell adhesion proteins, 
which may contribute to the reduced adhesion and delayed aggregation of cln3- cells 
[224]. Based on these findings, mass spectrometry was used to further explore the role 
of Cln3 in protein secretion, which ultimately provided the first evidence in any 
system linking CLN3 to this conserved cellular process [78]. Twelve proteins that are 
not normally secreted by wild-type cells during starvation were detected in 
conditioned buffer from cln3- cells [78]. In addition, two proteins that play a role in 
regulating adhesion during the early stages of multicellular development were not 
detected in cln3- conditioned buffer, which may help to explain into the aberrant 
adhesion of cln3- cells [78, 224]. Label-free quantification revealed 42 proteins that 
were present in significantly higher amounts in conditioned buffer harvested from 
cln3- cells and three proteins that were present in significantly reduced amounts [78]. 
Bioinformatic analyses performed on these hits revealed an enrichment of proteins 
linked to vesicle-mediated transport, endocytosis, metabolism, and proteolysis; 
processes that have all been linked to CLN3 function in mammals [78, 206, 233, 234]. 
The proteomic analysis also revealed altered amounts of Tpp1F, Cln5, and CtsD in 
cln3- conditioned buffer, providing evidence that Cln3 modulates the secretion of  
NCL protein homologs in Dictyostelium [78]. A subsequent study used western 
blotting to confirm that cln3-deficiency increases the secretion of Cln5 [235]. That 
study also showed that Cln3 co-localizes with Cln5 at the CV system, which has been 
linked to unconventional protein secretion in Dictyostelium [235, 236]. The results of 
this work can now be used to fuel research in human systems to determine how 
altered protein secretion may play a role in the pathology underlying CLN3 disease. 
In fact, the role of CLN3 in protein secretion was explored in subsequent studies 
using mouse and human models. More specifically, glia and neurons isolated from 
Cln3-deficient mice were shown to display altered protein secretion profiles [201]. In 
addition, mass spectrometry was used to show that samples of brain and cerebrospinal 
fluid from the three major forms of NCL (CLN1, CLN2, and CLN3 disease) all have 
altered protein content compared to normal individuals [231]. Together, these studies, 
coupled with the proteomic analysis of conditioned buffer harvested from 
Dictyostelium cln3- cells, suggests that the role of CLN3 in protein secretion warrants 
further investigation. 
RNA sequencing was performed to gain insight into the mechanisms underlying cln3-
deficiency phenotypes during the early stages of multicellular development [226]. 
That study revealed 1153 genes that were differentially expressed in cln3- cells 
compared to wild-type cells during starvation [226]. STRING and GO term analyses 
showed an enrichment of differentially expressed genes linked to metabolic, 
biosynthetic, and catalytic processes [226]. In addition, these analyses showed that 
loss of cln3 affects pathways related to Ras/MAPK signalling, glycan processing, and 
methionine and folate metabolism, which aligns with observations in mammalian 
models of CLN3 disease [237-242]. Among the differentially expressed genes were 
the Dictyostelium homologs of human TPP1/CLN2 (tpp1D and tpp1F), CTSD/CLN10 
(ctsD), PGRN/CLN11 (grn), and CTSF/CLN13 [226]. Not surprisingly, cln3-
deficiency was subsequently shown to alter Tpp1 and CtsD enzymatic activity [226]. 
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These data provide further support for the molecular networking of NCL proteins. 
Finally, loss of cln3 alters the expression and activity of lysosomal enzymes during 
starvation, specifically N-acetylglucosaminidase, alpha-mannosidase, and beta-
glucosidase [226]. These findings are consistent with the altered activity of these 
enzymes in post-mortem gray matter from NCL patient brains [243]. 
RNA sequencing was also used to better understand the role of Cln3 in 
osmoregulation in Dictyostelium [225]. During hypotonic stress, 320 genes were 
differentially expressed in cln3- cells compared to wild-type cells, and 162 genes were 
differentially expressed during hypertonic stress. Bioinformatic analyses showed that 
the differentially expressed genes are linked to developmental processes, which was 
confirmed by work showing that cln3- cells develop abnormally when subjected to 
osmotic stress [225]. Genes differentially expressed during hypotonic stress are also 
linked to metabolic processes [225]. Genes involved in transport and catalysis were 
differentially expressed during both osmotic stress conditions, which supports the role 
of Cln3 in protein secretion, including the secretion of proteases [78, 225]. Finally, 
loss of cln3 increases the expression of tpp1A during hypertonic stress, which was 
shown to correlate with increased Tpp1 activity [225]. In total, this work supports a 
role for Cln3 in osmoregulation, which should fuel research in mammalian models of 
CLN3 disease to determine how altered osmoregulation contributes to clinical 
phenotypes observed in NCL patients. This is especially relevant considering that 
osmoregulatory defects have also been reported in mammalian models of CLN3 
disease [218, 229]. 
 
6. CLN4 disease 
Homozygous mutations in the transmembrane protein DnaJ homolog subfamily C 
member 5 (DNAJC5), also known as cysteine string protein alpha (CSPa), cause 
CLN4 disease. 
 
6.1 Large animals  
No large animal models for CLN4 disease have been identified. 
 
6.2 Rodents 
The mouse homolog of CSP, a 198 amino acid protein encoded by mouse Dnacj5 
gene, shares 99% identity with human CSP (CLUSTALW (2.1) Multiple Sequence 
Alignment on Ensembl (www.ensembl.org)). CSP is a well-known synaptic vesicle 
protein. Before human DNAJC5 mutations were identified to cause CLN4 disease, 
Dnajc5 knockout mice had been produced to study CSP functions in synapses and 
neurodegenerative diseases. The Dnajc5 knockout mouse develops progressive 
synaptic- and neuro-degeneration, retinal degeneration, sensorimotor dysfunctions 
and a severely shortened lifespan [244, 245]. Further studies show that loss of the 
SNARE protein SNAP-25 in presynaptic compartments is the predominant cause of 
CSP-deficiency-associated neurodegeneration [246, 247]. Overexpression of human 
alpha-synuclein, which also performs a SNARE chaperoning function, in the CSP-
deficient mouse rescues the neuropathology in the brain, rescues the motor 
impairments,  and improves mouse survival [244]. More research into CLN4 disease 
is obviously still needed and the Dnajc5 knockout mouse could be a valuable 
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There are two versions of DNAJC5 in zebrafish, called Dnajc5aa and DNAJC5ab. 
Dnajc5aa is on chromosome 8 in a region with no synteny with the human homolog. 
This protein is 202 amino acids and has 81% identity at the protein level (CLUSTAL 
W (1.81) multiple sequence alignment on Ensembl (www.ensembl.org)).  Dnajc5ab, 
on the other hand, is on chromosome 23 in a region with a small amount of synteny 
with the human homolog, encompassing human DNAJC5, GUD8, SLC17A9, 
BHLHE23 on chromosome 20. Zebrafish Dnajc5ab is 199 amino acids long and has 
75% identity at the protein level (CLUSTAL W (1.81) multiple sequence alignment 
on Ensembl (www.ensembl.org)). Hence, synteny suggests that Dnajc5ab is the true 
homolog, but identity suggests that Dnajc5aa is more likely to have homologous 
function, though there may not be a large difference in function as the two homologs 
are 82% identical at the protein level. Both zebrafish proteins were found in 
synaptosomes from central synapses, similar to mouse Dnajc5 which is also found at a 
higher level in synaptosomes compared to post-synaptic densities [121].  Clearly more 
investigation is needed and it is likely that both genes will need to be mutated to make 
a zebrafish model of CLN4 disease. To date, no one has yet performed any 
experiments with these zebrafish genes. 
 
6.4 Fruit fly 
Cysteine string protein has perhaps been better studied in Drosophila than in any 
other model system since it was first identified in 1990 as the  antigen recognised by 
one of a set of classic neurobiology monoclonal antibodies generated from 
Drosophila heads [248]. It was subsequently named for its long string of cysteines. 
The single Csp gene in flies is widely expressed, including in all neurons. The protein 
localises to the neuropil of the larval and adult brain and is found in the synaptic 
terminals of the larval neuromuscular junction but not in the cell bodies of neurons. 
Mutations in Drosophila Csp severely affect neural transmission leading to locomotor 
defects, spasms and paralysis and a progressive neurodegeneration due to synapse 
failure [249, 250]. The phenotypes are somewhat temperature sensitive, consistent 
with a role for Csp as a chaperone. Csp appears to play several different roles in 
synaptic transmission. These include Ca2+-triggered exocytosis, regulation of pre-
synaptic Ca2+ levels and protection from thermal stress. Endocytosis of the synapse 
appears to be intact, however, in Csp mutants and not all of Csp’s pre-synaptic 
functions require binding to its chaperone partner, Hsc70 [251, 252]. 
 
6.5 Nematode 
C. elegans has a single homologue of the human DNAJC5 gene mutated in CLN4 
disease: dnj-14. The worm DNJ-14 protein displays extensive similarity to the human 
DNAJC5 gene product, cysteine string protein (CSP), in the DnaJ domain and the 
central cysteine string domain, with more sequence divergence apparent in the N- and 
C-terminal regions [253]. Notably, the two leucine residues within the cysteine string 
domain that are mutated in CLN4 disease (L115/L116) are conserved in C. elegans 
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DNJ-14 (L138/L139). To date, there has been no report of a direct CLN4 model 
whereby these leucines have been specifically mutated to mirror the human disease. 
However, because CLN4 disease ultimately results in the loss of CSP from its 
physiological location on synaptic vesicles due to aggregation and retention in the 
neuronal cell body [254-256], null mutants of C. elegans dnj-14 can be used as 
surrogate models of CLN4. The ok237 deletion allele contains a 2229 bp deletion that 
eliminates the great majority of the dnj-14 open reading frame and its promoter, and 
so is a molecular null exhibiting a complete loss of DNJ-14 protein expression. Young 
dnj-14 (ok237) mutant worms are essentially wild type for most phenotypes, although 
a very small reduction in locomotion is apparent. As the worms age, this locomotor 
impairment becomes progressively worse and a severe age-dependent chemosensory 
defect becomes apparent [253]. Normally, worms sense and move towards attractive 
sources, such as food and certain volatile compounds, but by 6-days-old, dnj-14 
(ok237) mutant worms have lost this chemotactic response. At 9-days-old, 
degeneration of sensory neurons in the head of dnj-14 (ok237) mutant worms 
becomes apparent, as seen by loss of fluorescence from GFP-labelled neurons, 
suggesting that the functional chemosensory impairment precedes morphological 
neurodegeneration. In keeping with these progressive, age-dependent phenotypes, 
dnj-14 (ok237) mutant worms exhibit a considerably reduced lifespan [253]. The large 
deletion in dnj-14 due to the ok237 allele also extends into a neighbouring gene, glit-
1, raising the potential concern that the observed phenotypes could be due to effects 
on glit-1. However, the lifespan and behavioural phenotypes of the ok237 allele were 
rescued by transgenic wild type dnj-14, and similar effects on lifespan and behaviour 
were observed using a smaller dnj-14-specific deletion allele, tm3223, or using RNAi 
knockdown of dnj-14 in an RNAi hypersensitive strain [253]. Taken together, these 
data indicate that the C. elegans dnj-14 null mutant model of CLN4 mirrors the 
human disease in terms of its late onset, progressive effects on the sensorimotor 
system, neurodegeneration and premature death. 
Genome-wide transcriptional profiling via DNA microarrays revealed a reduction in 
expression of genes involved in the ubiquitin proteasome system (UPS) – especially 
E3 ubiquitin ligases - in both the ok237 and tm3223 mutant strains [257]. Consistent 
with this, use of a GFP-tagged ubiquitin reporter revealed a decrease in ubiquitylated 
protein degradation in dnj-14 mutants [257]. These results indicate that disruption of 
the synaptic vesicle chaperone dnj-14 leads to reduced expression of UPS-related 
proteins, which in turn impairs proteasome-mediated protein degradation in the C. 
elegans model of CLN4. Given that proteasome inhibitor drugs are therapeutic in 
dnajc5 knockout mice [258], there appears to be an evolutionarily conserved role for 
the UPS in CLN4 disease The specific over-representation of E3 ubiquitin ligase 
components observed in worms [257] suggests that proteins and complexes upstream 
of the proteasome may potentially be beneficial therapeutic targets worthy of 
exploration in more complex models.  
One advantage of C. elegans over mammalian models is that compound screening can 
be performed quickly and cheaply with no ethical restraints. A focused drug screen 
identified the polyphenolic compound, resveratrol, as being able to ameliorate the 
various phenotypes of the C. elegans dnj-14 mutants [253]. Resveratrol’s 
neuroprotective effects are often ascribed to its ability to activate the protein 
deacetylase, SIRT1, but its therapeutic action in the dnj-14 model is unaffected by 
deletion of the worm SIRT1 orthologue, sir-2.1. Instead, it appears that resveratrol 
acts by inhibiting phosphodiesterases and thereby increasing cyclic AMP levels, as its 
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effects on the dnj-14 model are mimicked by the phosphodiesterase inhibitor rolipram 
[253]. Another compound that was found to rescue the dnj-14 mutant is the anti-
epileptic drug, ethosuximide [259]. Ethosuximide was shown to act via the DAF-
16/FOXO transcription factor, which is an evolutionarily conserved master regulator 
of stress resistance and longevity. Indeed, ethosuximide is effective in cell culture 
models of Huntington’s disease [259] and in a rat in vivo acute Alzheimer’s disease 
model [260], suggesting that it has general neuroprotective properties that could 
extend to other NCLs. Most recently, a screen of ethosuximide-related compounds 
identified α-methyl α-phenylsuccinimide to be over 100 times more potent than 
ethosuximide in a C. elegans TDP-43 neurodegeneration model [261]. It will be 
interesting to test whether the various neuroprotective compounds identified using the 
C. elegans dnj-14 model also have therapeutic activity in mammalian NCL models 
and hence have translational potential. 
 
6.6 Social amoeba 
The Dictyostelium homolog of human DNAJC5 appears to be the protein product of 
an uncharacterized gene, DDB_G0290017, which encodes a 176 amino acid, 20 kDa 
protein (DDB0306688). Within an 84 amino acid region of similarity between 
DDB0306688 and DNAJC5, 44% of the amino acids are conserved and 64% are 
positive matches. The expression of DDB_G0290017 is highest during growth and the 
protein product of the gene localizes to the macropinocytic pathway [80, 83]. Upon 
starvation, the expression of DDB_G0290017 decreases dramatically, reaching its 
lowest level as cells are aggregating into multicellular mounds [83]. Expression then 
remains low during the mid-to-late stages of development [83]. This expression 
profile suggests that the protein may function primarily during the growth phase of 
the Dictyostelium life cycle. As previously reported, the Dictyostelium genome 
encodes another protein (Ddj1, Dictyostelium DnaJ homolog 1) that shares sequence 
similarity with human DNAJC5 [62]. Ddj1 localizes to the centrosome, phagosome, 
and macropinocytic pathway and is predicted to play a role in phagocytosis [80, 262, 
263].  However, Ddj1 is significantly larger (411 amino acids, 46 kDa) than the 198 
amino acid human DNAJC5 protein and the alignment between the two proteins only 
encompasses a 69 amino acid region of similarity [62]. For these reasons, it is more 
likely that the protein product of the uncharacterized gene DDB_G0290017 is the 
Dictyostelium homolog of human DNAJC5. Knockout mutants of DDB_G0290017 
and ddj1 have not yet been generated. Therefore, future research will be required to 
determine which of the above-described proteins is the true homolog of human 
DNAJC5 in Dictyostelium.  
 
7. CLN5 disease 
Homozygous mutations in the lysosomal protein CLN5 cause CLN5 disease. 
 
7.1 Large animals  
7.1.1. CLN5 disease in dogs 
CLN5 mutations have been described in several breeds of dog. The Border collie 
NCL mutation (CLN5:c.619C > T ; [264]) is well known in breeding circles and 
pedigree dogs are routinely screened. More recently, the same CLN5 mutation was 
 32 
identified in Australian cattle dogs [265]. In addition, a different mutation 
(c.934_935delAG) causes CLN5 disease in Golden Retrievers [266]. Border Collies 
and Golden Retrievers with CLN5 disease display indistinguishable clinical 
development with symptom onset at around 13 months of age with terminal disease 
by three years old. These dogs may provide a useful addition/alternative to the sheep 
model for preclinical studies. 
7.1.2 CLN5 disease in Borderdale sheep 
The Borderdale sheep NCL was first described by Jolly et al. in 2002 [267]and 
subsequently confirmed to be caused by a mutation in CLN5 by Frugier and 
colleagues [268].  
Gene therapy efforts in the sheep flocks were initiated in 2008 with testing of 
lentiviral vectors [269, 270] and subsequently AAV9 vectors [270]. Initial testing 
using vectors expressing GFP, showed that lentiviral- mediated gene delivery was 
limited to the site of parenchymal injection or, following ICV injection, the ependyma 
and sub-ependymal layers. This low-level transduction was however sufficient for 
suppressing disease progression in CLN5 disease. AAV9 resulted in widespread 
expression from single sites of injection, however inflammatory responses were seen 
after parenchymal injections of AAV9-GFP and current studies focus on ICV 
administration ([270] and in preparation). Both lentivirus and AAV9 vectors 
expressing CLN5 protected sheep from development of behavioural deficits and 
pathology [271] when administered pre-symptomatically and AAV9-CLN5 stabilised 
disease when given after disease onset [272]. AAV serotypes differ in tropism 
between species and to date only AAV7 and 9 have been tested in sheep models 
[271]. It will be important when heading toward clinical trials to optimise the vector 
serotype used and test safety and toxicity in NHPs. These preclinical studies in sheep 
required the development of biomarkers. Extensive work has resulted in a suite of 
behavioural and clinical measurements [270], and electroencephalography (EEG), 
computed tomography (CT) [273], ERG [274] and imaging biomarkers that can be 
used to test additional therapeutic strategies. Combining electromyography (EMG), 
electrooculography (EOG) and electroencephalography (EEG) measurements allows 
sleep status to be evaluated [275, 276]. These later studies identified abnormal 
epileptiform activity and sleep abnormalities in CLN5 mutant sheep that could be 
traced longitudinally, similar to that seen in CLN5 patients. Combining these 




The mouse homolog of CLN5, a 341 amino acid protein encoded by mouse Cln5 
gene, shares 74% identity with human CLN5 (CLUSTALW (2.1) Multiple Sequence 
Alignment on Ensembl (www.ensembl.org)). Cln5 is widely expressed throughout the 
mouse brain and upregulation during brain development is remarkably observed [277, 
278]. In situ hybridization and immunohistochemistry on postnatal brain tissue reveal 
prominent Cln5 expression in cerebellar Purkinje cells, cerebral cortical neurons, 
hippocampal and hypothalamic neurons [277], though a different study on primary 
cell cultures suggests higher expression levels in glial cells than in neurons [278].  
A Cln5 knockout mouse line has been developed by disrupting exon 3 of Cln5 gene to 
model CLN5 disease [279]. Initial characterization of the model shows that it 
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reproduces several aspects of CLN5 disease such as progressive visual loss beginning 
from 13 weeks of age and autofluorescent storage material accumulation in the brain 
and retina [279].  Ultrastructural analysis of the cortical neurons with storage material 
accumulation shows typical fingerprint lamellar profiles [279]. Loss of GABAergic 
interneurons is observed in various brain regions by 6 months of age, while no 
obvious brain atrophy occurs at this stage [279]. A later study has further 
characterized this model, showing that significant neurodegeneration occurs as early 
as 4 months in the cerebral cortex and later in the thalamus while obvious brain 
atrophy and thinner cortical layers are observed by 12 months of age [280]. Also, 
recent research points to other neurobiological changes that might contribute to 
CLN5-deficiency-related neurodegeneration. Neurogenesis is found to be impaired in 
the Cln5 knockout mouse brain, as shown by impaired generation of mature neurons 
with normal neuritic morphology, in spite of increased neural progenitor cell 
proliferation [281]. Interestingly, astrocytosis appears to occur much earlier (1 month 
of age) compared to neurodegeneration [280], suggesting potential direct contribution 
of CLN5-deficient astrocytes to the disease and/or perhaps any early neural functional 
changes that could induce astrocytosis prior to neuronal loss. More research into the 
Cln5 knockout mouse at the stages prior to significant neurodegeneration also 
suggests early microgliosis and myelination deficits in the brain, plus systemic serum 
cholesterol elevation [278], which provides clues for potential unknown functions of 
CLN5 relevant to CLN5 disease, particularly in cell types other than neurons. 
Additionally, since progressive visual loss is a typical and early manifestation of 
CLN5 disease and the Cln5 knockout mouse also shows such a phenotype, the retinal 
pathology is of great interest in CLN5 studies. 
Characterization of retinal pathology in the Cln5 knockout mouse reveals progressive 
retinal photoreceptor cell apoptosis and glial infiltration beginning by 1 month of age 
[282]. The retinal outer nuclear layer shows dramatic atrophy by 3 months of age and 
further progresses with ageing [282]. Electroretinogram shows early-occurring and 
progressive rod-mediated functional decline, and cone-mediated functional decline at 
late stages [282]. In summary, the Cln5 mouse model represents an invaluable in vivo 
tool for studying CLN5 functions and CLN5 disease. However, further investigation 
of the model is still needed, such as to reveal deficits in behavioural performance and 
neurobiological changes relevant to the disease, as well as the mouse survival and 
endpoint manifestations, which could be particularly important for employing this 
model in novel therapy development and assessment.  
 
7.3 Zebrafish 
The zebrafish has one homolog of CLN5, found on chromosome 9 and encoding a 
protein of 329 amino acids. Zebrafish Cln5 is 55% identical to the human protein 
(CLUSTAL W (1.81) multiple sequence alignment on Ensembl (www.ensembl.org)) 
and there is a small syntenic region encompassing CLN5, FBXL3, MYCBP2 and 
SLAIN1. No experiments appear to have been performed to investigate zebrafish 
Cln5. 
 
7.4 Fruit fly 




C. elegans does not have a clear homologue of the CLN5 gene. 
. 
 
7.6 Social amoeba 
The Dictyostelium homolog of human CLN5 is a 322 amino acid, 37 kDa protein 
(Cln5) encoded by the cln5 gene [62]. Within a 301 amino acid region of similarity 
between Cln5 and CLN5, 30% of the amino acids are conserved and 47% are positive 
matches [62]. The Dictyostelium genome also encodes three additional 
uncharacterized proteins that share sequence similarity with human CLN5 
(DDB0346861, DDB0308005, and DDB0346698) [283]. However, the genes 
encoding these proteins (DDB_G0271546, DDB_G0279757, and DDB_G0293236) 
are all expressed at significantly lower amounts compared to cln5 [83]. The most 
significant discovery from work in Dictyostelium was that both Dictyostelium Cln5 
and human CLN5 have glycoside hydrolase activity [283]. This knowledge can now 
be used to fuel research in human models to develop therapies to restore the potential 
loss of glycoside hydrolase activity in patient cells. As in human cells, loss of Cln5 
function in Dictyostelium causes an accumulation of autofluorescent storage bodies 
within cells [235]. Recent work has shown that Cln5 is glycosylated in the ER and 
then trafficked to the cell cortex where it appears to be secreted via the CV system 
[78, 235, 283]. A proteomics-based analysis has also localized Cln5 to the 
macropinocytic pathway [80]. The secretion of Cln5 in Dictyostelium is consistent 
with the presence of a signal peptide for secretion in human CLN5, as well as the 
detection of CLN5 in conditioned media from cultured mammalian cells [283-285]. 
When Dictyostelium cells are starved, autophagy is induced, providing nutrients for 
multicellular development [286]. Intriguingly, Cln5 secretion is reduced when wild-
type cells are treated with lysosomotropic agents, suggesting that autophagic 
mechanisms regulate the secretion of the protein [235]. This result is in line with 
observations from mouse and human cell models of CLN5 disease that link the 
function of CLN5 to autophagy [282, 287]. The expression of cln5 increases 
dramatically during the early stages of development [83]. Upon starvation, cln5- cells 
display reduced cell-substrate adhesion, which is exacerbated when cells are treated 
with lysosomotropic agents, further supporting a link between Cln5 function and 
autophagy [235]. During this stage of the life cycle, cln5- cells also display reduced 
cell-cell adhesion [235]. These findings are consistent with the reduced adhesion of 
cells derived from Cln5-deficient mice and CLN5 disease patients [288, 289]. As a 
likely consequence of the reduced adhesion, Dictyostelium cln5- cells also display 
defects in chemotaxis during the early stages of multicellular development [235]. 
Finally, Dictyostelium Cln5 interacts with lysosomal enzymes (e.g., beta-glucosidase, 
alpha-mannosidase), cysteine proteases, other homologs of NCL proteins (e.g., 
Tpp1B, CtsD, DDB0252831/similar to CTSF), and proteins linked to Cln3 function in 
Dictyostelium (e.g., AprA, CfaD, CadA) [283]. In addition, ten Cln5-interactors are 
differentially secreted by cln3- cells, providing further support for the molecular 
networking of NCL proteins in Dictyostelium [78, 283]. In total, work from 
Dictyostelium shows that Cln5 is secreted during the early stages of multicellular 
development and suggests that it may function as a glycoside hydrolase to modulate 
adhesion. Future studies can now utilize this knowledge to examine the role of 
extracellular CLN5 in the pathology underlying NCL. 
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8. CLN6 disease 
Homozygous mutations in the CLN6 transmembrane protein cause CLN6 disease. 
 
8.1 Large animals  
8.1.1 CLN6 disease in sheep 
The CLN6 South Hampshire (New Zealand) flock has been key to understanding 
pathology, and more recently, testing therapies in a large animal brain. In vivo 
pathology and identification of storage has been extensively reviewed previously 
[290]. Here we focus on data published since 2013 and reported at NCL2018 
(www.ncllondon2018.com). The availability of tissue samples continues to allow 
comparative pathology and testing of biomarkers. Embryonic sheep brain 
preparations, first developed in the 1990s [291, 292] have been recently used to 
establish early (pre-storage body) changes in the autophagy/lysosome and endocytotic 
pathways [293], and for testing of drug [293, 294] and gene therapy strategies [291] 
prior to in vivo testing. The relatively large brain provides ample cells for multiple 
studies and refinement of methods for storage of single cell suspensions in liquid 
nitrogen provides for a continued supply of cells from the same group of animals 
[269]. Similarly, use of body fluids, including urine, have been used to establish 
additional biomarkers that might be useful in preclinical trials [295] . Drug trials in 
sheep are limited by costs (mg/kg required compared to small models) and metabolic 
differences between ruminants and humans. Based on earlier reports that glial 
inflammation precedes neuronal loss in CLN6 sheep [296], Kay and Palmer tested 
chronic oral administration of minocycline, an antibiotic with anti-neuroinflammatory 
effects. While pharmacologically relevant levels of minocycline were detected in the 
brain, no significant effects on neuroinflammation or disease progression were found 
[297].  
The South Hampshire [12] and Merino [298] flocks have different CLN6 mutations, 
The South Hampshire sheep have a deletion in exon 1.  The Merino sheep have a 
point mutation c.184C>T resulting in p.Arg62Cys which is the subject of proteasome 
mediated degradation (Neverman and Hughes, unpublished). While mortality is 
reportedly earlier in the Merino (19-27 months compared to 25-30 months in South 
Hampshire) this may be reflective of pastural conditions between sites rather than 
disease associated differences. The Merinos have not yet been used in preclinical 
studies, however preparatory biomarker and clinical course studies have been done on 
a small number of sheep [299]. More extensive analysis and experience with the 
South Hampshire flock over the last 3 decades have established a suite of pathological 
and behavioural data sets (reviewed in [290]).  Most recently this flock have been 
used for gene therapy trials [290]. The only effective gene therapy in CLN6 mutant 
sheep was in pre-symptomatic sheep treated with AAV9. This was effective in 1/3 
and 1/6 sheep [272] in respective trials suggestive that gene therapy is possible in this 
form of the disease. Establishing why only some sheep respond to treatment will be 




The mouse homolog of CLN6 shares 92% amino acid identity with human CLN6 
(CLUSTALW (2.1) Multiple Sequence Alignment on Ensembl (www.ensembl.org)). 
The mouse Cln6 gene is mapped to chromosome 9. Upregulation of Cln6 expression 
during postnatal development is observed in the developing mouse brain, especially in 
the cerebral cortex and cerebellum [300]. In the adult mouse, Cln6 is widely 
expressed throughout the brain, and in situ hybridization reveals localized expression 
in the cerebral cortex, cerebellar Purkinje cell layer, and hippocampal DG and CA1 
cell body layers [300]. An insertion mutation in exon 4 of mouse Cln6 resulting in a 
frameshift truncation is the cause of a murine form of NCL (nclf), thus the nclf mouse 
appears to be a naturally occurring mouse model for human CLN6 disease [19-21].  
Behavioural manifestations and CNS pathology of the nclf mouse have been 
characterized. Although the mice appear to be normal until 8 months of age when 
they start to develop progressive hind limb paralysis [19], research employing rotarod 
tests reveals that significantly impaired motor coordination is evident by 3 months of 
age [301]. Impaired memory and learning performance is also reported in the mouse 
[301]. Characterization of the pathology in the nclf mouse shows accumulation of 
lysosomal storage material in the CNS beginning postnatally [19], and by 12 months 
of age strong autofluorescence accumulation is widely observed throughout the brain 
[302]. Early-onset gliosis in the nclf mouse brain is another hallmark of the model, 
which is consistent with the CLN6 sheep model [296, 302]. Furthermore, prior to 
observation of neurodegeneration, the nclf mouse displays significant synaptic and 
axonal pathology at the pre/early-symptomatic stages, as shown by cortical spine 
density decrease, dysregulated synaptic protein levels in the thalamocortical system, 
demyelination and axonal degeneration in the spinal cord and decreased internal 
capsule volume [19, 301, 303]. Such pathology suggests the existence of early neural 
functional changes potentially contributing to the behavioural phenotype of the model 
before neuronal loss. Additionally, progressive retinal degeneration is another early 
event in the nclf mouse [301, 304, 305]. Similar to the brain pathology, astrocytosis 
and autofluorescent storage material accumulation are also observed in the retina at 
early stages [304, 305]. The mouse then exhibits impaired visual acuity by 8 months 
of age [304, 305]. Interestingly, a recent study has found a significant difference in 
the disease progression between male and female nclf mice, with the female mouse 
showing accelerated autofluorescence accumulation and behavioural deficits [306].  
As CLN6 disease is a monogenetic disease due to CLN6 deficiency, gene therapy is 
an attractive approach. An earlier study testing effects of AAV gene therapy on the 
retinal phenotype of the nclf mouse showed that intravitreal administration of AAV 
variant 7m8 vectors with CLN6 rescued the photoreceptor cell loss in the retina [307]. 
A preclinical study of AAV9 gene therapy, where the human CLN6 gene was under 
the control of the chicken -actin promoter, using the nclf mouse was recently 
reported at NCL2018: significant improvements were seen in motor performance, 
learning and memory and survival, as well as a reduction in autofluorescent storage 
material [308]. Subsequent test on Cynomolgus Macaques demonstrated no adverse 
effects and high levels of the transgene in the brain and spinal cord [308]. Safety trials 
for intrathecal gene therapy for CLN6 disease have since begun [309].  
 
8.3 Zebrafish 
Zebrafish have two homologues of CLN6, called Cln6a and Cln6b. Cln6a is a 298 
amino acid protein on chromosome 7 with 68% identity with human CLN6 
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(CLUSTAL W (1.81) multiple sequence alignment on Ensembl (www.ensembl.org)).  
Only two genes, CLN6 and CALML4, are syntenic. Cln6b may code for three 
proteins of different lengths – 309, 310, 241 amino acids. It is on chromosome 26, has 
synteny over four genes, CALML4, CLN6, FEM1B, ITGA11, but has only 57% 
identity (for the 310 amino acid protein) (CLUSTAL W (1.81) multiple sequence 
alignment on Ensembl (www.ensembl.org)).   
Three alleles of cln6a have been generated (Table 3). A further four alleles were 
reported at NCL2018. One has been examined for a phenotype and homozygotes 
appear to be normal, adult viable and fertile, with normal electroretinograms [211]. 
Knock down of the Cln6a protein has not yet been demonstrated in these alleles. 
 
8.4 Fruit fly 
Drosophila has no clear homologue of the CLN6 gene. 
 
8.5 Nematode 
C. elegans does not have a clear homologue of the CLN6 gene. 
. 
 
8.6 Social amoeba 
The Dictyostelium genome does not encode a homolog of human CLN6. 
 
9. CLN7 disease 
CLN7 disease is caused by homozygous mutations in the transmembrane protein 
called Major facilitator superfamily domain-containing protein 8 (MFSD8). 
 
9.1 Large animals  
9.1.1 CLN7 disease in dogs 
Dog models of CLN7 NCL have recently been described in the Chinese -crested dog 
[310] and Chihuahua [311] (Table 1), however research colonies are not currently 
established.  
9.1.2 CLN7 disease in monkeys  
The first genetically confirmed monkey NCL was reported in 2018 [18]. The Japanese 
macaque disease is caused by a frameshift mutation in CLN7, c769delA, which causes 
a truncated protein, MFSD8. Monkeys presented clinically at around 5 years with 
symptoms including incoordination, ataxia, hindlimb weakness and impaired balance. 
Six monkeys were followed from three until six years. Progressive loss of cerebral 
and cerebellar volume was observed by magnetic resonance imaging (MRI), and 
retinal degeneration tested using optical computed tomography (OCT) and ERG. 
Hallmark pathology including autofluorescent storage material and gliosis were also 
found in the brain at necropsy. This model is now being established as a research 
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colony at the Oregon National Primate Research Center, providing the first NHP 
model with which to study therapeutic strategies. 
 
9.2 Rodents 
The mouse homolog of MFSD8 shares 81% amino acid identity with human MFSD8 
(CLUSTALW (2.1) Multiple Sequence Alignment on Ensembl (www.ensembl.org)). 
The first Mfsd8 deficient mouse model was generated in 2014, reproducing typical 
NCL-like pathology such as autofluorescent storage material accumulation and gliosis 
throughout the brain and retinal degeneration [312]. Since this mouse model still 
expressed low levels of Mfsd8, the same research group developed another Mfsd8 
knockout mouse model with no detected Mfsd8 expression in the brain [313]. The 
knockout mouse exhibited clasping, hind limb paralysis, seizures and a shortened 
lifespan [313]. Pathology in the brain included autofluorescent storage material 
accumulation, accumulated mitochondrial ATP synthase subunit c and saposin D, and 
brain gliosis [313]. Furthermore, upregulated expression of lysosomal cathepsins and 
accumulated autophagic proteins in the brain of the knockout mouse suggested 
impaired autophagy-lysosomal pathway [313]. Additionally, the knockout mouse also 
showed retinal pathology including retinal degeneration, microgliosis and lysosomal 
dysfunction [314]. In future, this mouse model, together with the monkey CLN7 
disease model [18], could be a valuable tool for pre-clinically studying novel 
therapies for CLN7 disease.  
 
9.3 Zebrafish 
Zebrafish chromosome 12 harbours the homolog of human MFSD8 with a syntenic 
region that spans MFSD8, ZCCHC4, ABLIM2 and AFAP1. Zebrafish Mfsd8 has 504  
amino acids with 61% identity with human MFSD8 protein (CLUSTAL W (1.81) 
multiple sequence alignment on Ensembl (www.ensembl.org)). Five mutations exist 
in the gene. They have not yet been investigated to see if they provide a suitable 
model for CLN7 disease (Table 3). Three further alleles were created by gene editing 
and one was examined for phenotypes in homozygotes but they were adult viable and 
fertile with no obvious health defects, as presented at NCL2018 [211]. The 
consequence of these mutations on the protein still needs to be examined.  
 
9.4 Fruit fly 
Drosophila has one MFSD8/CLN7 homologue. A recent study generated a YFP-Cln7 
fusion knock-in construct by CRISPR/Cas9 gene editing to allow the expression and 
sub-cellular localisation of Cln7 protein to be assessed without overexpression. This 
line, together with a second line in which the Cln7 promoter drives expression of a 
nuclear RedStinger protein, reveals widespread expression of Cln7 but a surprisingly 
restricted expression within the CNS. Drosophila Cln7 is largely restricted to glia in 
the larval CNS and only expressed in neurons in the developing visual system [217]. 
As with Cln3, Cln7 is expressed in the glia that comprise the blood brain barrier along 
with other glia along the midline of the ventral nerve cord. At the larval 
neuromuscular junction, Cln7 expression is restricted to the post-synaptic muscle and 
apparently absent from the pre-synaptic nerve. Interestingly, Cln7 is recruited to the 
post-synaptic membrane where it co-localises with Dlg, the Drosophila homologue of 
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PSD-95. This mirrors the localisation of human Cln7 in receptor the outer plexiform 
layer of the retina where it also co-localises with PSD-95 [315]. A Cln7 mutant 
generated by imprecise excision of a transposable element reveals a requirement for 
Cln7 for the normal development of the synapse (Connolly et al, submitted: available 
at bioRxiv: https://www.biorxiv.org/content/10.1101/278895v3).  Given the 
localisation of Cln7 to the post-synaptic side of the synapse, this suggests a role in 
retrograde signalling across the synapse. 
 
9.5 Nematode 
The C. elegans genome encodes a large number of proteins with significant similarity 
to the human MFSD8 protein based on BLASTP analysis. Of these, six display more 
than 29% amino acid identity over 95% of the full length protein sequence: 
Y53G8AR.7, ZK550.2, F14D7.6, T28C12.1, T28C12.2 and W05E10.1 (Table 4). All 
that is known about the function of these genes is that RNAi knockdown of 
Y53G8AR.7 increases resistance to the oxidative stressor, paraquat, and increases 
lifespan [316]. It is unclear which of the worm MFSD8 homologues corresponds to 
the human protein and it may be that there is considerable genetic redundancy among 
the numerous paralogues. If so, construction of strains containing multiple mutation 
might be required. Given that there are no currently available deletion mutants, this 
would represent a significant challenge. It therefore seems unlikely that a worm 
model of CLN7 disease will be developed in the near future.  
 
9.6 Social amoeba 
The Dictyostelium homolog of human MFSD8 is a 498 amino acid, 55 kDa protein 
(Mfsd8) encoded by the mfsd8 gene [62]. Within a 530 amino acid region of 
similarity between Mfsd8 and MFSD8, 29% of the amino acids are conserved and 
47% are positive matches [62]. Like other homologs of NCL proteins in 
Dictyostelium, Mfsd8 localizes to the macropinocytic pathway [80]. The expression of 
mfsd8 remains relatively constant throughout the Dictyostelium life cycle, but peaks 
after 8 hours of development, suggesting that the protein may play a role in cAMP-
mediated chemotaxis and aggregation [83]. Future work that generates and 
characterizes a Dictyostelium mfsd8 knockout mutant is likely to provide novel insight 
into the precise function of MFSD8 in human cells and the processes it regulates. 
 
10. CLN8 disease 
CLN8 disease is caused by homozygous mutations in the transmembrane protein 
CLN8. 
 
10.1 Large animals  
10.1.1 CLN8 disease in dogs 
The English Setter dog was the first described naturally occurring dog model [13] and 
has been extensively studied and reviewed [317].  There has been confirmation of the 
English Setters mutations as being in CLN8 [318], and additional mutations in the 
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Australian Shepherd [319] and Alpenlandisiche Dachsbracke [320] have been 
identified (Table 1). None of these models have been used recently. 
 
10.2 Rodents 
The mouse homolog of CLN8 shares 84% amino acid identity with human CLN8 
(CLUSTALW (2.1) Multiple Sequence Alignment on Ensembl (www.ensembl.org)). 
Mouse Cln8 is ubiquitously expressed in various tissues, and particularly, upregulated 
in the developing brain [321].  
A homozygous Cln8 mutation causes a naturally occurring mouse NCL (mnd) [22-
25]. The mnd mouse develops typical NCL pathology, such as autofluorescent storage 
material accumulation, gliosis, neurodegeneration and retinal degeneration [23, 322, 
323]. Also, autofluorescent storage material accumulation and lysosomal abnormality 
are observed in peripheral tissues particularly in the liver [322]. The mnd mouse 
exhibits motor coordination impairment and decreased learning and memory [24, 324-
326]. The mnd mouse is thus a valuable model for studying CLN8 functions and 
CLN8 disease. Several studies have suggested pathways that might be involved in 
CLN8 disease progression. ER stress and mitochondrial deficits are found in the mnd 
brain at pre-symptomatic stages [327, 328]. A recent study employing the mnd mouse 
model and in vitro culture systems found that CLN8 is required for lysosomal enzyme 
trafficking [329]. To date, no pre-clinical therapeutic study has been performed in the 
mnd mice.  
 
10.3 Zebrafish 
The zebrafish Cln8 protein is 289 amino acids long with 54% identity with human 
CLN8 (CLUSTAL W (1.81) multiple sequence alignment on Ensembl 
(www.ensembl.org)). Cln8 is encoded by a gene on chromosome 17 which has 
synteny with human CLN8, ARHGEF10, KBTBD11. One zebrafish strain containing 
mutation in cln8 has been generated but not yet investigated (Table 3). 
 
10.4 Fruit fly 
Drosophila has no clear homologue of CLN8. 
 
10.5 Nematode 
C. elegans does not have a clear homologue of the CLN8 gene. 
. 
 
10.6 Social amoeba 
The Dictyostelium genome does not encode a homolog of human CLN8. 
 
11 CLN10 disease 
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Homozygous mutations in the lysosomal enzyme Cathepsin D (CTSD) cause CLN10 
disease. 
 
11.1 Large animals  
CLN10 mutations have been identified in the American Bulldog and Swedish 
Landrace Sheep (Table 1). In contrast to the sheep which show congenital disease 
[330] and complete loss of Cathepsin D (CatD) activity, the bulldog has a protracted 
presentation with onset around two years of age and terminal disease by 7 years and 




The mouse homolog of cathepsin D (CTSD) shares 80% amino acid identity with 
human CTSD (CLUSTALW (2.1) Multiple Sequence Alignment on Ensembl 
(www.ensembl.org)). Ctsd null mice have been used to model human CLN10 disease. 
The CTSD deficient mice are born normally, and then from around 2 weeks of age 
they develop behavioural deficits (seizures and motor abnormalities) and typical 
pathology of NCLs (neuronal lipofuscin deposition, lysosomal accumulation of 
mitochondrial ATPase subunit c, microgliosis and neurodegeneration), and die at the 
age of P26±1 [331-333]. Apart from brain pathology, severe visceral pathology is also 
observed, such as destruction of intestine and lymphoid organ, which might be the 
main lethal factor  [333]. Early functional and structural synaptic alterations are 
observed in the Ctsd null mouse, especially in the thalamus and hippocampus [334, 
335]. Ctsd null mice also show deficient myelination and lipid metabolism in the 
brain [335-338]. A study delivering AAV vectors with mouse Ctsd into the brain of 
the Ctsd null mice shows improvement of both the CNS and visceral pathologies and 
prolonged lifespan until around 2 months of age when the mice die from recurrent 
visceral pathology [339]. Surprisingly, the lethal recurrent visceral pathology was not 
accompanied by development of any NCL-like CNS pathology [339]. Cumulatively, 
CTSD appears to play some vital roles in the periphery in mice. It calls into question 
whether it is equally important for humans, and if so, preclinical work of gene therapy 
via systemic delivery may be necessary. 
 
11.3 Zebrafish 
Chromosome 14 harbours the zebrafish ctsd gene in a region without synteny with the 
human. The single homolog encoded by this gene is 59% identical to human 
Cathepsin D (CTSD) (CLUSTAL W (1.81) multiple sequence alignment on Ensembl 
(www.ensembl.org)). mRNA is maternally deposited and becomes stronger in the 
brain and yolk syncytial layer as development progresses [120, 340]. In the adult it is 
expressed in many tissues, including strong expression in the brain [341]. The Ctsd 
protein was found in the synaptosome compartment in central synapses of adult 
zebrafish, similar to the situation in mouse where Ctsd is found in higher levels in the 
synaptosome compared to post-synaptic densities [121]. Processing of zebrafish Ctsd 
is slightly different from CTSD in humans and this may be relevant to the 
interpretation of some studies [342]. 
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Antisense morpholinos have been injected into embryos to knock down Ctsd in 
zebrafish embryos and larvae [340, 343]. In 2011, Follo et al. demonstrated many 
phenotypes in common with zebrafish lacking Tpp1, such as lack of a swim bladder, 
curved tail, larger yolk sac, micropthalmia and premature death from 3 - 10 dpf using 
the T-MPO morpholino. They went on to demonstrate a lack of microvilli on the 
retinal pigmented epithelial cells, which normally express high levels of Cathepsin D, 
but did not define the mechanism by which this results in micropthalmia [340] . It 
would be interesting to compare retinal phenotypes in zebrafish lacking Tpp1, Cln3 
and Ctsd and define their relationships and mechanisms in common. Given that CLN6 
seems to be required in the inner nuclear layer in mice [307], there may be multiple 
mechanisms causing retinal degeneration. 
Follo et al. next examined the somites and musculature in straight zebrafish lacking 
Ctsd (T-MPO injected). They found a reduction in myofibres and thinner myosepta 
[343]  This phenotype was seen at 4 dpf and it is not yet clear if the phenotype is due 
to a defect within the muscle itself or if the phenotype is an indirect consequence of 
loss of Ctsd in another tissue. It is possible that abnormal, or reduced numbers of, 
motor neurons could result in muscle phenotypes. Alternatively, the zebrafish skeletal 
muscle may be uniquely sensitive to levels of Ctsd as such a phenotype has not yet 
been reported in the mouse [344]. One mutation exists in zebrafish ctsd, which has not 
yet been investigated for a phenotype (Table 3). 
 
11.4 Fruit fly 
CLN10 disease has been modelled in Drosophila by generating a loss-of-function 
mutant in the one cathepsin D homologue, cathD [345]. Mutant flies exhibit a low-
level accumulation of autofluorescent storage material in the brains of ageing adult 
flies, there is no effect on lifespan and only a small number of apoptotic cells are 
detectable in the brains of older flies [345]. This mild phenotype is in contrast to the 
congenital onset of disease in human CLN10 disease patients and is surprising given 
that scRNA-seq indicates strong expression of cathD in neurons and glia throughout 
the adult fly brain. The visual system of cathD mutant flies do display a low level of 
vacuolation, indicative of degeneration. This phenotype was used as the basis of a 
small-scale candidate screen searching for genes capable of enhancing or reducing 
vacuolation, which identified a potential role in endocytosis, oxidative stress 
responses and cholesterol trafficking [346]. The mild phenotype of the cathD mutant 
flies has also proven useful to demonstrate the importance of lysosomal function in 
the pathology of late-onset forms of neurodegeneration: both -synuclein and Tau 
pathology is enhanced dramatically in a cathD mutant background [347, 348]. 
 
11.5 Nematode 
Several aspartic-type endopeptidases are encoded in the C. elegans genome, but the 
closest homologue of human CTSD (cathepsin D) is asp-4. Based on GFP fusion 
protein analysis, ASP-4 protein localises to the lysosome and is highly expressed in 
the worm intestine, although lower level expression in various other cell types, 
including neurons, is evident [349]. To date, there are no reports claiming asp-4 to be 
a worm model of CLN10. Nevertheless, asp-4 has been shown to play important roles 
in neurodegeneration. Early work established that the non-apoptotic, necrotic cell 
death of mechanosensory neurons induced by various neurodegenerative triggers was 
 43 
dependent on the activity of just two aspartyl proteases: ASP-3 and -4. RNAi 
knockdown of asp-4 was shown to suppress degeneration of mechanosensory 
neurons, whereas overexpression of ASP-4 exacerbated neurodegeneration [349, 
350]. In contrast, RNAi knockdown of asp-4 has been shown to exacerbate transgenic 
α-synuclein accumulation while overexpression is protective against α-synuclein-
induced dopaminergic neuron degeneration [351]. It seems, therefore, that asp-4 is an 
important regulator of neurodegeneration that can act in a positive or negative manner 
depending upon the context. Further work on asp-4 as a potential model for CLN10 
disease is clearly warranted. 
 
11.6 Social amoeba 
The Dictyostelium homolog of human CTSD is a 383 amino acid, 41 kDa protein 
(CtsD) that localizes throughout the endocytic pathway, including phagosomes, 
macropinosomes, and lysosomes [80, 352-354]. Within a 359 amino acid region of 
similarity between CtsD and CTSD, 47% of the amino acids are conserved and 66% 
are positive matches [62]. CtsD is secreted by Dictyostelium cells during starvation, 
which is consistent with the presence of a signal peptide for secretion in both the 
Dictyostelium and human proteins [78]. The expression of ctsD is highest during 
growth [83]. ctsD expression decreases dramatically during the first 4 hours of 
starvation and then increases between 4 and 8 hours [83]. Expression then steadily 
decreases during the mid-to-late stages of development [83]. This expression profile 
suggests that CtsD may function primarily during growth and aggregation. ctsD-
deficiency has no obvious effects on Dictyostelium growth or development, except for 
a slight delay in aggregation, which is consistent with the secretion of CtsD during 
this stage of the life cycle [78, 354]. Insight into the function of CtsD in Dictyostelium 
has been obtained through indirect studies. For example, ctsD expression is 
downregulated 10-fold in cells lacking the DNA-binding protein serum response 
factor B (SrfB) [355]. srfB-deficiency in Dictyostelium reduces proliferation, impairs 
cytokinesis, increases pinocytosis, and causes aberrant aggregation [355]. These 
phenotypes, coupled with the dramatic reduction in the expression of ctsD in srfB- 
cells, the delayed aggregation of ctsD- cells, and the secretion of CtsD during the early 
stages of multicellular development, suggests that CtsD is required for optimal 
aggregation in Dictyostelium. In addition, these findings are supported by work in 
mammalian cells that reported reduced migration of CTSD-deficient cells due to the 
abnormal organization of cytoskeletal elements [356]. In human cells, this 
abnormality is predicted to impact neurogenesis, neuronal migration, and the 
maintenance of neuronal polarity and shape [356]. Work in Dictyostelium has also 
linked CtsD function to bacterial killing and cell death. When Dictyostelium cells are 
infected with Salmonella typhimurium, the agent of food-borne gastroenteritis, they 
activate a defense response that upregulates the expression of cysteine proteases, 
including ctsD [357]. These observations are consistent with studies in mice that have 
linked CTSD function to the innate immune response against Listeria monocytogenes 
infection [358]. CtsD in Dictyostelium is also speculated to play a role in 
staurosporine-induced cell death, as well as oxidative stress-induced cell death [359, 
360]. In line with these results, CTSD function has been linked to staurosporine-
induced apoptosis in human fibroblasts and oxidative stress-induced cell death in 
human cancer cells [361, 362]. In total, these findings indicate that the function of 
human CTSD is likely conserved in Dictyostelium and future work in this model 
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organism may be able to provide new insight into the function of CTSD in human 
cells and how mutations in CTSD cause CLN10 disease. 
  
12. CLN11 disease 
CLN11 disease is caused by homozygous mutations in the soluble protein Granulin 
(GRN). 
 
12.1 Large animals  
There are no large animal models of CLN11 disease. 
 
12.2 Rodents 
Similar to the GRN expression in the human brain, GRN is predominantly expressed 
by neurons and microglia in the adult mouse brain [363-365]. A Grn knockout mouse 
line was initially generated to study the role of progranulin in mouse sexual dimorphic 
behaviours[366]. Further research showed that aged Grn knockout mice displayed 
extensive autofluorescent lipofuscin accumulation and gliosis by light microscopy and 
abundant rectilinear profiles by electron microscopy in brain neurons, which is typical 
of NCLs [363, 367]. Such findings were also observed with the use of other 
independently generated Grn knockout mouse lines [368, 369]. Transcriptomic 
analysis revealed altered expression profiles of lysosomal genes in the brain of young 
adult Grn knockout mice [370, 371], suggesting lysosomal dysregulation as an early 
event in the mouse Grn null brain. Lipidomic analysis of the brain tissue from Grn 
knockout mice and from human patients with heterozygous-GRN-mutation-associated 
frontotemporal lobar degeneration (FTLD) showed specific lipidomic profiles distinct 
from healthy controls and other neurodegenerative patients without GRN deficiency 
[370], which suggests one of the potential mechanisms underlying GRN-related 
neurodegeneration and also indicates some extent of comparability between the 
human GRN deficient brain and the Grn knockout mouse brain. However, distinct 
neurodegeneration is not evident in the Grn knockout mice, except for appearance of 
vacuolation with ageing in the hippocampal CA2-3 regions and the habenular nucleus 
of the Kayasuga et al.’s mouse model that might suggest focal neuronal loss [363, 
372]. Significant neuronal loss in the hippocampus was detected in the aged Grn 
knockout mice generated by Petkau et al., but it appeared to be mouse strain 
dependent and only present in the mice on the B6 background [373]. Behaviourally, 
although deficits were reported in Grn knockout mice, such as increased aggression, 
altered social behaviour and learning impairment [366, 373, 374], results are to some 
extent variable and still need further confirmation. It seems, therefore, that mouse 
models have somewhat limited benefits for modelling the progression of CLN11 
disease, and thus development of large animal models that share more similarities 
with humans may be necessary.  
Progressive vision loss due to retinal dystrophy is one of the clinical features in 
CLN11 patients. Retinal changes were thus studied in the Grn knockout mice. The 
adult Grn knockout mice generated by Kayasuga et al. exhibited significant retinal 
ganglion cell loss and retinal astrocyte activation, which was already observed as 
early as P9 [375]. Moreover, increased retinal autofluorescence, thinning of the outer 
nuclear layer and reduced rhodopsin (rod photoreceptor marker) were also found in 
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these mice [376, 377]. With the use of an independent mouse line [364], progressive 
retinal lipofuscinosis and retinal ganglion cell loss were also detected [378, 379]. 
Therefore, the Grn knockout mouse model might be a pre-clinical tool for developing 
therapies against retinal abnormalities of CLN11 disease that could somewhat 
improve the life quality of patients, though further retinal functional analysis and 
visual assessment of these mice need characterisation. 
As GRN is highly expressed by both neurons and microglia, one interesting question 
is whether microgliosis contributes to CLN11 disease pathogenesis or whether it is 
just secondary to neuronal pathology. In a study investigating the effects of GRN 
deficiency on acute MPTP-induced neurotoxicity in the mouse brain, Grn knockout 
accelerated the neuronal loss induced by MPTP treatment, which is replicated by 
microglial-specific conditional Grn knockout [364]. The mechanism may involve a 
microglial phenotype induction towards a more pro-inflammatory state and 
subsequent enhanced neuronal death [364]. Additionally, microglial lysosomal 
function impairment occurs earlier than the lysosomal abnormalities in other cell 
types in the Grn knockout mouse brain, indicating a vulnerability of microglia to 
PGRN deficiency [380]. Thus, microglial GRN appears to play an important role in 
regulating microglial functions.  However, the exact contribution of such role to the 
disease process of CLN11 still need further study. Interestingly, mice with conditional 
Grn knockout selectively targeting either neurons or microglia do not replicate the 
typical NCL pathology that the constitutive Grn null mice have shown [381, 382], 
indicating requirement of complete GRN depletion for CLN11 disease development 
and probably a non-cell autonomous manner of GRN function.  
GRN gene therapy has been studied pre-clinically on the Grn knockout mouse model. 
A study employing intracranial (intraparenchymal) injection of AAV vectors with 
GRN into  Grn knockout mice at 10-12 months of age, when they have already 
developed the NCL pathology, showed promising improvements of neuronal 
lipofuscin accumulation, microgliosis and lysosomal dysfunction in various brain 
regions, despite a very limited transduction area [368]. However, another recent study 
on GRN gene therapy via AAV intraventricular injection on the Grn knockout mice 
showed that GRN overexpression caused delayed dramatic hippocampal 
neurodegeneration accompanied by marked T-cell infiltration that preceded the 
neurodegeneration [372]. The hippocampal damage did not seem to be due to the viral 
vector injection or overexpressing a transgene in mice null of that gene, as there was 
no evident toxicity caused by AAV-eGFP injection into the Grn knockout mice or 
AAV-SGSH injection into an Sgsh knockout mouse model. So it might be a direct 
effect of excessive GRN expression and/or corresponding adaptive immune response. 
Such toxicity was not reported by Arrant et al.’s study we discussed earlier [368]. 
Notably, in that study the AAV-GRN vector injection induced a strong immune 
response at the injection site and systemic production of anti-GRN antibody in the 
mouse plasma, though no brain damage was observed [368]. Given that in Arrant et 
al.’s study the mice were harvested only 8-10 weeks after AAV injection [368] but in 
Amado et al.’s study the neuronal damage occurred with a delay relative to AAV 
injection [372], it is difficult to conclude that the GRN gene therapy and 
corresponding immune response induced in Arrant et al.’s study would have no 
adverse effects in the long term. In the case of CLN11 disease research, further study 
is definitely needed to investigate functions of GRN. In vitro models may be 
particularly useful for studying GRN functions in regulating immune cells and GRN-
overexpression-induced neuronal toxicity. More broadly, the importance of long-term 
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The zebrafish genome contain two homologs of GRN with multiple granulin domains, 
as seen in the human gene, and two homologs with far less granulin domains. grna 
encodes a protein that has 12 granulin domains and granb encodes a protein that has 9 
granulin domains, whereas grn1 and grn2 encode only 1.5 granulin domains each 
[383]. It is therefore not expected that grn1 or grn2 is the homolog of human GRN. 
grna on chromosome 3 is in a small syntenic region containing just human GRN and 
IFI35. It encodes a 1049 amino acid protein which has only 18% identity at the 
protein level (CLUSTAL W (1.81) multiple sequence alignment on Ensembl 
(www.ensembl.org)). The mRNA is predominantly expressed in the intermediate cell 
mass, which houses precursors of blood and immune cells (including microglia) in the 
developing embryo, in spinal cord motor neurons [384-386], and in the brain and 
many tissues in the adult [384]. grnb mRNA expression is restricted to the brain in 
embryos and is found in the various tissues including the brain in the adult [384]. The 
gene is located on chromosome 24 where there is synteny with the human 
chromosome synteny with the human chromosome encompassing GRN, MAP3K14, 
ARL17A, ARL17B, GRB7 and STCIN1. The encoded Grnb protein is 729 amino 
acids long and it has 25% identity at the protein level (CLUSTAL W (1.81) multiple 
sequence alignment on Ensembl (www.ensembl.org)). Wang et al. examined the 
structure of modules within the zebrafish Grn proteins and found that only Grna and 
Grnb contained modules that folded as expected. On testing the ability of a module 
from Grna, it was found to promote survival of neuronal cells in NSC 34 cells, but the 
module from Grnb was not tested [387].  It is difficult to determine, therefore, which, 
if any, of Grna and Grnb might be the direct homolog of human GRN.   
Several papers report the effects of knockdown of Grna and Grnb. Most recently 
Solchenberger et al. reported a lack of phenotypes, after extensive investigations, in 
maternal zygotic grna-/-;grnb-/-, as well as zygotic double mutants and single 
mutants [383]. This somewhat contradicted previous studies where phenotypes were 
seen in motor axons and muscle cell precursors using antisense morpholino 
oligonucleotides against grna [385, 388, 389]. Walsh et al. also saw  cells stuck in the 
cell cycle during retinal neurogenesis after injection with grna morpholinos [386] It is 
tempting to explain this by suggesting that the morpholinos cause off-target effects, 
but this is unlikely as the short motor axon phenotype can be rescued by injection of 
grna mRNA [385, 388]. Therefore, it may be that there is a compensatory mechanism 
that is only induced by the mutation. Further studies will help to distinguish the true 
roles of zebrafish Grna and Grnb, but this means that at the moment we are not 
completely satisfied that we have generated a suitable model of CLN11 disease in 
zebrafish. Four further mutants for grna and two for grnb currently exist and await 
description (Table 3).  
Further experiments have tested the protective role of Grna. grna mRNA injected into  
embryos engineered to have altered levels of TDP-43, FUS and Smn1 [385, 388, 390] 
rescue the TDP-43 and FUS induced phenotypes.  
 
12.4 Fruit fly 
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Drosophila has no clear homologue of the GRN gene. 
 
12.5 Nematode 
The C. elegans progranulin orthologue, pgrn-1, encodes a protein with three predicted 
granulin domains, compared with the 7.5 granulin domains in human progranulin 
[391]. Analysis of fluorescent transcriptional reporters indicates that pgrn-1 gene 
expression occurs in neuronal and intestinal cells throughout larval development and 
into adulthood. In contrast, a translational reporter using a fluorescent protein fused to 
PGRN-1 was not localised to specific tissues, suggesting that the worm protein is 
secreted [391]. Null mutants of pgrn-1 appear superficially wild type and have a 
normal lifespan, but exhibit a 20% reduction in fecundity as measured by the total 
number of progeny produced. More importantly, worms lacking progranulin exhibited 
a more rapid clearance of apoptotic cells, an effect that could be partially rescued by 
reintroduction of the wild type pgrn-1 gene [391]. Such a defect in programmed cell 
death kinetics could potentially contribute to neuronal loss over the lifetime of human 
progranulin-mutation carriers. Although a neurodegenerative phenotype was not 
observed in C. elegans pgrn-1 mutants, this may be because adult worms do not 
exhibit programmed cell death in somatic tissues, unlike vertebrates. Interestingly, 
pgrn-1 mutants are resistant to some (heat, osmotic and endoplasmic reticulum stress) 
but not all environmental stressors, a phenotype shared by mutations in other genes 
affecting distinct aspects of the apoptotic process [392]. A neuroprotective role for 
pgrn-1 that may relate more obviously to CLN11 disease is suggested by the 
observation that the PGRN-1 acts downstream of TDP-43 in a pathway that 
ameliorates the toxic effects of polyglutamine protein expression in a worm 
Huntington’s disease model [393]. A further link to TDP-43 comes from the 
observation that heterozygous pgrn-1 mutants exhibited worsened TDP-43 toxicity, 
although homozygous pgrn-1 mutants did not [394]. Intriguingly, transgenic 
expression of granulins 2 and 3 (but not granulin 1) exacerbated the toxicity of co-
expressed TDP-43, as indicated by defects in behaviours including locomotion and 
fecundity [394]. A recent pre-print has claimed that granulins selectively interact with 
the aspartyl protease ASP-3/cathepsin D in  C. elegans, impairing its enzymatic 
activity and hence lysosome function [395]. This direct connection between two 
proteins implicated in distinct CLN diseases revealed in C. elegans has potentially 
important mechanistic and therapeutic implications. 
 
12.6 Social amoeba 
The Dictyostelium homolog of human PGRN, Grn, shares sequence similarity with 
human GRNs 1–7 [66]. The grn gene encodes a 130 amino acid, 14 kDa protein.  
Within a 47 amino acid region of similarity between Grn and PGRN, 55% of the 
amino acids are conserved and 68% are positive matches [62]. Expression of grn is 
highest during growth [83]. Upon starvation, expression decreases dramatically 
reaching its lowest level during the mid-to-late stages of multicellular development 
[83]. This expression profile suggests that Grn likely functions during growth and 
may not be essential for aggregation or differentiation. Future work that generates and 
characterizes a grn-deficient Dictyostelium cell line may be able to provide insight 
into the primary function of PGRN in human cells and how mutations in this gene 
cause CLN11 disease.  
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13. CLN12 disease 
CLN12 disease is caused by homozygous mutations in the transmembrane 
protein ATPase Cation Transporting 13A2 (ATP31A2). 
 
13.1 Large animals  
The only confirmed cases of CLN12 disease in large animals was found in Tibetan 
terriers [396, 397]. While mutations in CLN12, encoding ATP13A2 can cause Kufor-
Rakeb syndrome, an early onset Parkinson’s disease, the dogs display a late-onset 
NCL, also now confirmed in human cases [398]. 
 
13.2 Rodents 
Mouse Atp13a2 is mapped to chromosome 4 [399], and the encoded protein shows 
>80% identity with human ATP13A2 (CLUSTALW (2.1) Multiple Sequence 
Alignment on Ensembl (www.ensembl.org)). It is expressed in all mouse tissues and 
shows particularly high expression in the brain at the transcriptional level [399]. Two 
research groups have generated and characterized Atp13a2 knockout mouse lines 
independently [400-402]:both lines develop and reproduce normally and display 
typical NCL features at old age, such as motor deficits and neuronal lipofuscin 
accumulation and gliosis throughout the CNS. Another mouse line with brain-specific 
conditional Atp13a2 knockout also confirms that ATP13A2 deficiency in the mouse 
brain resembles late-onset behavioural phenotypes (motor impairments) and typical 
NCL pathological characteristics (neuronal lipofuscin accumulation positive for 
mitochondrial ATPase subunit c) [403]. Interestingly, astrocytosis is found to occur 
much earlier (1 month of age) compared to other pathology such as lipofuscin 
accumulation (12 months of age) and the behavioural deficits (18 months of age) in 
the Atp13a2 null mouse [400]. Particularly, heterozygous Atp13a2 knockout mice 
show high-level astrogliosis throughout the CNS without robust lipofuscinosis [401], 
suggesting a potential independent role of ATP13A2 in astrocyte function. However, 
although it has been suggested that astrocyte ATP13A2 deficiency induces 
accelerated astrocyte inflammatory cytokine release in vitro [404], contribution of 
astrocyte ATP13A2 in CLN12 disease is still unclear and further study is needed to 
investigate the ATP13A2-deficiency-induced in vivo astrocyte changes at 
subcellular/molecular levels.  
As ATP13A2 mutations are also involved in Kufor-Rakeb syndrome (KRS, a genetic 
form of Parkinson’s disease), researchers investigated alpha synuclein aggregation 
and dopaminergic pathology in the Atp13a2 null mice. In contrast to the NCL 
pathology, the ATP13A2 deficient mice do not significantly show CNS alpha 
synuclein pathology or dopaminergic neuronal changes in the substantia nigra [400-
402], suggesting the Atp13a2 knockout mouse alone may not be an ideal model to 
recapitulate Parkinson’s disease. However, with respect to CLN12 disease, Atp13a2 
null mice clearly provide a valuable mammalian model for investigating the disease 




The zebrafish encodes a homolog of ATP13A2 on the atp13a2 gene located on 
chromosome 23.  Atp13A2 is 1170 amino acids, with 51% identity with human 
ATP13A2 (CLUSTAL W (1.81) multiple sequence alignment on Ensembl 
(www.ensembl.org)). The small region of synteny encompasses ATP13A2 and SDHB 
only. Expression of atp13a2 mRNA is initially everywhere at 12 hpf, but soon 
becomes restricted to the brain [120, 405]. Knockdown using antisense morpholino 
oligonucleotides results in reduced embryonic survival, small eyes, a curved body, a 
large yolk sac and impaired locomotion, which are all phenotypes in common with 
Tpp1 [28] and Ctsd [340] knockdown zebrafish. However, others failed to generate a 
phenotype with morpholinos against ATP13A2 [213].  Five mutant alleles exist, 
which have not yet been investigated (Table 3).  
 
13.4 Fruit fly 
Drosophila has a clear homologue of ATP13A2 encoded by the anne boleyn (anne) 
gene (CG32000). scRNA-seq data indicate anne is highly expressed in most neurons, 
potentially all. Studies of anne are limited. However, knockdown of anne in neurons 
in the Drosophila CNS leads to accumulation of storage material in lysosomes that 
worsens with age, accompanied by increased insoluble ubiquitinated proteins. These 
phenotypes can be suppressed by overexpression of HDAC6 [406].  
 
13.5 Nematode 
catp-6 is the closest C. elegans homologue of human ATP13A2, although catp-5 and 
catp-7 also show significant homology. It seems there is some redundancy in function 
between these three paralogues, as although single null mutants are viable, catp-6; 
catp-5 and catp-6; catp-7 double mutants are sterile [407]. Studies using fluorescent 
proteins fused to CATP-6 suggest that the protein is expressed in various cell types, 
including neurons, where it localises to cortical vesicular structures [407]. Null 
mutant catp-6 worms are slow growing, exhibit uncoordinated locomotion, and have 
significantly reduced fecundity as determined by the number of progeny reaching the 
L4 larval stage within 2 days [407]. Transgenic expression of catp-6 in dopaminergic 
neurons ameliorated the degeneration of these cells induced by co-expressed α-
synuclein, whereas RNAi knockdown of catp-6 exacerbated dopaminergic 
neurodegeneration [408]. These findings are clearly relevant for Parkinson’s disease, 
given its established link to mutations in ATP13A2/PARK9, but may also have 
implications for CLN12 disease. 
 
13.6 Social amoeba 
The Dictyostelium homolog of human ATP13A2 is Kil2, a P-type ATPase that 
contains 10 putative transmembrane domains [62, 409]. The 1158 amino acid, 131 
kDa Kil2 protein is encoded by the kil2 gene.  Within a 1089 amino acid region of 
similarity between Kil2 and ATP13A2, 35% of the amino acids are conserved and 
53% are positive matches [62, 409]. Like other NCL protein homologs in 
Dictyostelium, Kil2 is present in the macropinocytic pathway [80]. Expression of kil2 
increases steadily during development reaching peak levels during fruiting body 
formation, suggesting that the protein plays a role in differentiation [83]. Kil2 
localizes to the phagosomal membrane and kil2-deficiency impairs the ability of cells 
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to kill ingested Klebsiella pneumoniae bacteria [409, 410]. However, this defect 
appears to be species-specific, since kil2- cells can kill several other species of 
bacteria without impairment (e.g., B. subtilis and P. aeruginosa) [409]. The impaired 
ability of kil2- cells to destroy ingested Klebsiella pneumoniae can be restored by 
supplementing the medium with magnesium [409]. These results suggest that Kil2 
functions as a magnesium pump to maintain the optimal concentration of magnesium 
in phagosomes, thereby enabling the activity of phagosomal proteases [409]. Recent 
work also indicates that the role of Kil2 in killing Klebsiella pneumoniae may involve 
vacuolar protein sorting protein 13F (Vps13F) [411]. Interestingly, VPS proteins have 
been linked to the function of NCL protein homologs in yeast [412, 413]. Finally, the 
function of Kil2 has also been linked to the predation of Dictyostelium amoeba on 
yeast [414]. In mammalian cells, ATP13A2 localizes to the lysosome and is 
speculated to function as a biometal transporter [415, 416]. As a result, the protein has 
been linked to processes that rely on biometal transport, such as autophagy [406, 417]. 
In total, work on Kil2 function supports the putative role of human ATP13A2 in 
maintaining biometal homeostasis in lysosomes and indicates that the future study of 
Kil2 in Dictyostelium may reveal novel insight into the function of ATP13A2 that is 
lost in patients with CLN12 disease. 
 
14. CLN13 disease 
Homozygous mutations in the lysosomal enzyme Cathepsin F (CTSF) cause CLN13 
disease. 
 
14.1 Large animals  
There are no large animal models of CLN13 disease. 
 
14.2 Rodents 
Mouse cathepsin F shares >80% identity with human human Cathepsin F [418]. The 
encoding gene was identified to be on mouse chromosome 19 and expressed 
ubiquitously in various mouse tissues [418]. Widespread expression of mouse 
cathepsin F in the CNS and its lysosomal localization was also confirmed [419]. 
Before mutation in human CTSF was identified as the pathogenic gene in CLN13 
disease, a Ctsf null mouse model had been generated by homologous recombination, 
exhibiting a late-onset NCL-like phenotype [419]. The Ctsf null mouse does not show 
obvious phenotypes (progressive hindlimb weakness and motor coordination 
impairment) until 12-16 months of age, and dies within the following 4-6 months 
[419]. Neuronal autofluorescent storage material accumulation accompanied by 
astrogliosis and neurodegeneration was observed in the CNS of the Ctsf null mouse 
model [419, 420]. Electron microscopic analysis revealed lamellated inclusions in the 
spinal cord neurons of Ctsf null mice [419, 420], though no increase was found in the 
levels of mitochondrial ATPase subunit c [419, 420]. Future work employing this 
mouse model may provide important information on in vivo functions of cathepsin F 
and may reveal biological mechanisms underlining how CTSF deficiency results in 




Zebrafish Ctsf is 473 amino acids, 47% identical to the human homolog (CLUSTAL 
W (1.81) multiple sequence alignment on Ensembl (www.ensembl.org)) and encoded 
by the ctsf gene on chromosome 14. There is only one ctsf gene in zebrafish and it sits 
in a very small region of synteny that is made of TRPT1 and CTSF. The mRNA is 
known to be expressed in the adult retina [421] and in the brain and spinal cord during 
development [120]. Five mutations exist but a phenotype has not yet been reported 
(Table 3). 
 
14.4 Fruit fly 
The Drosophila Ctsf homologue is encoded by CG12163. It is expressed widely 
throughout the CNS but has not yet been studied in the context of the NCLs. Multiple 
lines are available to study CG12163, including UAS-RNAi lines and potential 
insertional mutants (see flybase.org).  
 
14.5 Nematode 
The predicted product of the C. elegans temporarily assigned gene tag-196 displays 
49% amino acid identity to Cathepsin F over a 300-amino-acid stretch among its 487-
amino-acid full-length sequence. According to WormBase, tag-196 is expressed in 
various tissues, including muscle, intestine, the reproductive system and neurons. 
Although four different predicted null mutant alleles are available, there are no 
published data on the phenotypes of these mutants, so the physiological function of 
tag-196 in C. elegans is unknown. 
 
14.6 Social amoeba 
A previous study identified cysteine proteinase A (CprA) as the likely homolog of 
human CTSF in Dictyostelium [62]. The cprA gene encodes the 343 amino acid, 39 
kDa CprA protein.  Within a 340 amino acid region of similarity between CprA and 
CTSF, 37% of the amino acids are conserved and 55% are positive matches [62]. 
CprA is speculated to play a role in the digestion of proteins to provide amino acids 
for developing cells [422]. cprA is not expressed during growth, but expression, 
which is induced by extracellular cAMP, increases dramatically during the early 
stages of development [83, 423]. cprA has also been identified as a pre-stalk specific 
gene [424]. CprA contains a signal peptide for secretion and is secreted during 
Dictyostelium development, which is consistent with the secretion of CTSF in humans 
[78, 425]. Indirect studies have provided insight into the function of CprA in 
Dictyostelium. For example, the expression of cprA is induced during hypertonic 
stress suggesting that the protein plays a role in osmoregulation [426]. Expression is 
also upregulated during starvation in response to rpkA-deficiency [427]. Receptor 
phosphatidylinositol kinase A (RpkA) is a seven transmembrane G-protein coupled 
receptor (GPCR) that localizes to phagosomes and is involved in the phagocytosis of 
infectious bacteria [428]. Importantly, this work is consistent with the proposed role 
of CTSF in cell immunity in mammalian cells [429]. Also, rpkA-deficiency impairs 
aggregation due an inability to respond to extracellular cAMP [427]. Given the 
increased expression of cprA in rpkA- cells, and the dramatic increase in cprA 
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expression upon starvation, these findings indicate that CprA may play a role in 
cAMP-mediated chemotaxis and aggregation.  
While CprA has been identified as the likely homolog of human CTSF in 
Dictyostelium, there are several additional cysteine proteases that share sequence 
similarity with the human protein. Among these proteins are cysteine proteinase B 
(CprB, 376 amino acids, 33% conserved amino acids and 47% positive matches 
within a 342 amino acid region of similarity) and the uncharacterized protein 
DDB0252831 (352 amino acids, 37% conserved amino acids and 52% positive 
matches within a 339 amino acid region of similarity, encoded by gene 
DDB_G0291191). Based on their size and similarity, either of these proteins could 
also be the Dictyostelium homolog of human CTSF. Like CprA, both proteins are 
secreted by Dictyostelium cells during starvation [77, 78]. Protein DDB0252831 also 
localizes to endocytic vesicles and the macropinocytic pathway [80, 430]. The 
expression profile of cprB is almost identical to that of cprA [83]. Like cprA, the 
expression of cprB is induced by extracellular cAMP and cprB is characterized as a 
pre-stalk specific gene [423, 424]. However, unlike cprA and cprB, gene 
DDB_G0291191 (protein DDB0252831) is expressed at high levels during growth 
[83]. Expression then decreases dramatically upon starvation, reaching its lowest level 
after 8 hours of development, and remains low during the mid-to-late stages of 
multicellular development [83]. This expression profile suggests that protein 
DDB0252831 functions primarily during growth, which is supported by previous 
work that linked the protein to the cellular response to bacterial pathogens [431]. 
Taken together, these findings indicate that protein DDB0252831 may function as the 
dominant CTSF-like protein during growth, while CprA and CprB may both function 
as the primary CTSF-like proteins during development. Gene-deficiency models have 
not yet been generated for cprA, cprB, or gene DDB_G0291191 in Dictyostelium. 
Therefore, future work to generate and characterize cells lacking these genes should 
provide insight into their functions, and hopefully shed light on which of these genes 
is the true homolog of human CTSF in Dictyostelium. 
 
15. CLN14 disease 
Homozygous mutations in Potassium Channel Tetramerization Domain Containing 7 
(KCTD7) cause CLN14 disease. Sequence analysis suggests that the protein may 
function as a voltage-gated potassium channel.  
 
15.1 Large animals  
There are no large animal models of CLN14 disease. 
 
15.2 Rodents 
Mouse Kctd7 at chromosome 5 encodes the mouse homolog of human KCTD7. The 
protein sequence of mouse KCTD7 is ~97% identical to human KCTD7 
(CLUSTALW (2.1) Multiple Sequence Alignment on Ensembl (www.ensembl.org)). 
It has been shown that KCTD7 is widely expressed in both developing and adult 
mouse brains, especially in the hippocampus, cerebral cortex and cerebellum [432, 
433]. However, the in vivo function of KCTD7 in the mouse brain is still not clear, 




Chromosome 10 of the zebrafish harbours the sole zebrafish homolog of KCTD7. 
Synteny extends from CUX1, through to KCTD7 and RABGEF. The encoded protein 
is 339 amino acids, with 62% identity with the human protein (CLUSTAL W (1.81) 
multiple sequence alignment on Ensembl (www.ensembl.org)). No phenotype has yet 
been reported for the four mutations that exist (Table 3) and there are no studies so far 
showing mRNA or protein localisation. 
 
15.4 Fruit fly 
Drosophila has no clear homologue of KCTD7. 
 
15.5 Nematode 
The C. elegans genome encodes numerous predicted proteins with significant 
similarity to human KCTD7. It is unclear which, if any, of these represents the 
KCTD7 orthologue and therefore might represent a potential model for CLN14 
disease. 
 
15.6 Social amoeba 
A previous study reported that the Dictyostelium homolog of human KCTD7 is 
Kctd9, which is a 488 amino acid, 53 kDa protein that is encoded by the kctd9 gene 
[62]. Kctd9 contains four penta-peptide repeats, a double-courtin domain, and is 
highly similar to potassium channel tetramerization domain-containing proteins found 
in vertebrates [66]. Within a 96 amino acid region of similarity between Kctd9 and 
KCTD7, 38% of the amino acids are conserved and 58% are positive matches [62]. 
The expression of kctd9 decreases during the early stages of development and reaches 
its lowest level after 4 hours of starvation [83]. Expression then increases 
significantly, reaching its peak level by 12 hours, after which time expression 
decreases steadily during the mid-to-late stages of development [83]. In addition to 
Kctd9, there are three additional proteins encoded by the genome that are similar to 
human KCTD7 (DDB0238663, DDB0346929, and DDB0347398 encoded by genes 
DDB_G0269760, DDB_G0285861, and DDB_G0269022, respectively). These three 
proteins are similar in sequence to human KCTD7 (33-38% conserved amino acids 
and 49-60% positive matches within a 95-99 amino acid region of similarity), but 
unlike Kctd9, are more similar in size to human KCTD7 (346-366 amino acids vs. 
488 amino acids for Kctd9 vs. 289 amino acids for KCTD7). Future work on Kctd9 
and the three uncharacterized proteins may shed light on which protein is the true 
Dictyostelium homolog of human KCTD7. Once this is established, Dictyostelium can 
be used a model system to study how mutations in human KCTD7 cause CLN14 
disease. 
 
16. Concluding remarks 
This review presents an update on the range of multicellular model organisms and 
disease models being used for NCL research, in the hope that this will stimulate 
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researchers to collaborate and employ the most suitable model(s) for their study. This 
is particularly important before a therapeutic enters clinical trial, where positive 
outcomes from studies using more than one organism will reduce the risk of failure. 
It is evident that the choice of model organism to be used for a study is first 
determined by the existence of a clear homologue, particularly when considering 
using an invertebrate. However, this implies that other parts of a pathway that is 
conserved in humans and vertebrates may be missing in invertebrates. Nonetheless, 
the power of these organisms for mechanistic studies is undeniable.  
The zebrafish is being increasingly used and embryonic/larval disease models such as 
those for CLN2 and CLN3 disease are the only vertebrate models that can be cheaply, 
quickly and easily used for drug discovery.  Certainly, more NCL disease models 
could be generated and validated in the zebrafish, and many mutants exist that have 
not yet been examined for an NCL-like phenotype. Issues with zebrafish include 
identifying the correct homologue to target when more than one exists, or the possible 
need to knock down both homologues. In this organism, knock-down induced using 
different means seems to result in different phenotypes (if any) – further research is 
needed to uncover why this is, but one tantalizing possibility is the existence of one or 
more novel compensation mechanisms that suppresses phenotypes induced by certain 
types of mutation. This is also true in Dictyostelium where multiple homologs exist 
for some of the NCL proteins (e.g., homologs of TPP1 and CTSF). One caveat to 
using Dictyostelium as a biomedical model is the limited number of cell types in the 
organism, which may ultimately limit the translation of findings to specific tissues or 
organs in mammalian systems. Nonetheless, the presence of 11 homologs of NCL 
proteins in Dictyostelium, coupled with genetic tractability of the organism, suggests 
that future work in Dictyostelium has the potential to shed new insight on the 
functions of NCL proteins in human cells. With this in mind, the Dictyostelium 
research community is very active in generating knockout models to study the 
functions of the various NCL protein homologs in this organism. The nematode 
worm, being the smallest and simplest of all animal models, provides an intermediate 
between zebrafish and Dictyostelium. Although its short lifespan and facile molecular 
genetics make it attractive for modeling NCLs, relatively few CLN disease genes 
have been investigated in detail in C. elegans. This is due at least in part to the lack of 
obvious homologues for several genes, but for those genes with clear worm 
orthologues, it is anticipated that new and improved C. elegans models will be 
developed in the near future.  
Mouse models have been, and continue to be, the mainstay of NCL research. 
However, phenotypes often take a long time to develop and do not always faithfully 
recapitulate the cognate human disease. In such cases, initial studies using in vivo 
models with a faster disease onset or displaying phenotypes in additional relevant 
tissues, may be useful. For example, despite a greater need for gene therapy for CLN3 
disease, this has been pioneered first in the mouse model of CLN6 disease because it 
has a faster onset and progression. 
Large animals displaying NCL are undeniably useful for therapeutic testing, usually 
after initial testing on smaller organisms. Until recently, we have relied upon 
naturally-occurring large animal models but the recent implementation of gene editing 
in veterinary species is providing an increasing range of relevant large animal models. 
Together, multicellular models of NCL have been, and will continue to be, crucial for 
understanding pathology and testing new therapies. Understanding the relative 
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strengths and weaknesses and comparing findings in multiple model systems will aid 
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Table 1. The use of existing large animal models in NCL research. 
Large animal model species Gene mutation Examples of use for pathology/basic research Use in pre-clinical studies 
Dogs    
Dachshund CLN1:c.736_737 insC [86] Original description only - 
Cane Corso CLN1:c.124+1G > A [87] Original description only - 
Dachshund CLN2:c.325delC [27] Retinal pathology[434] Gene therapy, enzyme replacement, 
Stem cells 
Border Collie CLN5:c.619C > T [264] Biomarkers[264] - 
Golden Retriever CLN5:c934_935delAG [266] Original description only - 
Australian Shepherd CLN6:c.829T >C [435] Original description only - 
Chinese crested dog, 
Chihuahua 
CLN7:c.843delT [311] Original description only - 
English Setter CLN8:c491T >C [436] [437] Carnitine supplementation [438] 
Australian Shepherd CLN8:c.585G  >A [319] Original description only - 
Alpenlandische Dachsbracke CLN8:g.30852988_30902901del [320] Original description only - 
Saluki CLN8:c.349dupT [439] Original description only - 
American Bulldog CLN10:c.597G >A [318] Original description only - 
Tibetan Terrier CLN12:c.1623delG [440, 441]   
Sheep    
Borderdale (NZ) CLN5:c.571+1G>A [268] Primary neural cultures[291, 293], 
biomarkers[275, 276, 295], synaptic changes 
[442] 
Gene therapy [270, 272] 
South Hampshire (NZ) CLN6 Extensive characterization since 1970s, primary 
neural cultures[293], biomarkers[295], glial 
pathology[296]  
Gene therapy, minocycline drug trial 
[297] 
Merino (Australia) CLN6:c.184C>T [443] Biomarkers[299] - 
Swedish Landrace (Finland) CLN10 [330]  
Monkey CLN7:c.769del [18] Original description only - 
Cattle     
Devon (Australia) CLN5:c.662dupG [444] Original description only - 
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Table 2. The available murine models in NCL research. 
Disease (causative gene) Mouse model Original reference Pre-clinical studies 
CLN1 (PPT1)    
 Ppt1 knockout mouse [95] AAV gene therapy [115-119] 
Recombinant PPT1 [112, 113] 
Thioesterase mimicking drug [108, 109, 114] 
 Ppt1 knockout mouse [96] - 
 Ppt1 (R151X) knock-in mouse [105] - 
 Ppt1 (R151X) knock-in mouse [106] Nonsense suppression therapy [106] 
CLN2 (TPP1)    
 Tpp1 knockout mouse [29] AAV gene therapy [137, 151-154] 
Enzyme replacement [138, 156-158] 
Gemfibrozil [159] 
 Tpp1 (R207X) knock-in mouse [150] - 
CLN3 (CLN3)    
 Cln3 knockout mouse [176, 178] Glutamate receptor antagonist [183, 184, 445] 
 Cln3 knockout mouse [177] - 
 Cln3
 Δex7/8 knock-in mouse 
 
[175] AAV gene therapy [204, 205] 
Phosphodiesterase-4 inhibitor [208] 
Trehalose [209] 
 Cln3 reporter knock-in mouse [173] Carbenoxolone [169] 
CLN4 (DNAJC5)    
 Dnajc5 knockout mouse [245] Overexpression of alpha-synuclein [244] 
CLN5 (CLN5)    
 Cln5 knockout mouse [279] - 
CLN6 (CLN6)    
 Naturally occurring nclf mouse [19] AAV gene therapy [307] 
CLN7 (MFSD8)    
 Mfsd8 knockout mouse [312, 313] - 
CLN8 (CLN8)    
 Naturally occurring mnd mouse [22, 24] - 
CLN10 (CTSD)    
 Ctsd knockout mouse [333] Anti-inflammatory therapy [332] 
CLN11 (GRN)    
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 Grn knockout mouse [366] AAV gene therapy [372] 
 Grn knockout mouse [369] - 
 Grn knockout mouse [364] [368] 
 Grn knockout mouse [374, 446] - 
CLN12 (ATP13A2)    
 Atp13a2 knockout mouse [400] - 
 Atp13a2 knockout mouse [402] - 
 Atp13a2 conditional knockout (brain-
specific) mouse 
[403] - 
CLN13 (CTSF)    
 Ctsf knockout mouse [419] - 
CLN14 (KCTD7)    
 No murine models - - 
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Table 3. Zebrafish homologues of human NCL genes, available models and known associated phenotypes. 




Molecular defect Phenotype Journal 
articles  
CLN1/PPT1  Ppt1 ppt1sa9 nonsense mutation/predicted protein truncation after 
exon2 
not described  
  ppt1sa7888 nonsense mutation/predicted protein truncation after 
exon 3 
not described  
CLN2/TPP1  Tpp1 tpp1sa11 nonsense mutation/predicted protein truncation after 
exon 3 results in loss of protein by 
immunofluorescnce 
small eyes and head at 2 dpf, lethality by 7 dpf, 
SCMAS increases, apoptosis increases, reduced 
cell proliferation, lysotracker increases, activity 
increased at 3 dpf and decreased at 4 dpf 
[28] 
  tpp1sa2895 essential splice site for exon 9 not described  
  tpp1sa6483 nonsense mutation/predicted protein truncation after 
exon 10 
not described  
  tpp1hu3587 nonsense mutation/predicted protein truncation after 
exon 11 
normal [28] 
  tpp1sa8389 nonsense mutation not described  
  tpp1 
ATG/splice 
site MOs 
splice MO affects splicing small eyes and head at 2 dpf [28] 
CLN3 Cln3 cln3 sa20092 nonsense mutation in exon 10 not described  
  cln3 
ATG/splice 
site MOs 
splice site MO affects splicing small eyes and head at 2 dpf, lethality at 5 dpf, 
activity increased at 36 hpf and decreased at 4 
dpf, astrocytosis, apoptosis increases, reduced 
cell proliferation, lysotracker increases, SCMAS 
increases, mitochondrial membrane potential 
altered 
[210] 
CLN4/DNAJC5 Dnajc5aa     
 Dnajc5ab     
CLN5 Cln5     
CLN6 Cln6a cln6asa904 essential splice site for exon 6 not described  
  cln6asa10876 nonsense mutation not described  
  cln6ala016089Tg retroviral insertion not described [447, 448] 
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 Cln6b cln6bsa37974 splice site not described  
CLN7/MFSD8 Mfsd8 mfsd8sa2646 essential splice site for exon 5 not described  
  mfsd8la018118Tg transgenic insertion not described [447, 448] 
  mfsd8sa27950 nonsense mutation  not described  
  mfsd8sa42028 nonsense mutation  not described  
  mfsd8sa45459 splice site for exon 12 not described  
CLN8 Cln8 cln8sa25040 not described not described  
CLN10/CTSD Ctsd ctsdsa36610 nonsense mutation/predicted protein varies according 
to transcript 
not described  
  CD T-MPO  complete protein knockdown micropthalmia (RPE microvilli  affected), 
shorter body, swim bladder not inflated, hyper-
pigmentation, impaired yolk absorption (all at 
4dpf), premature death (10dpf) 
[340, 343] 
CLN11/GRN Grna grna sa6034 nonsense mutation/predicted protein varies according 
to transcript 
not described  
  grna sa20026 nonsense mutation/predicted protein varies according 
to transcript 
not described  
  grnasa38396 splice site/exon affected varies according to transcript not described  
  grnasa33188 splice site/exon affected varies according to transcript not described  
  grnamde33 1bp deletion in exon 3 normal [383] 
  grnamde54a 11bp deletion in exon 3 normal [383] 
  grnamde54b 11bp deletion in exon 3 normal [383] 
  grnamde54c 1bp insertion/11 bp deletion in exon 3 normal [383] 
  grna MO 
(various) 
severe protein knockdown, reduction assessed by RT 
PCR 
reduced motility, widespread disruption of CNS 
development, motoneuron axon truncation and 




 Grnb grnbsa30129 nonsense mutation in exon 15 not described  
  grnbsa37944 nonsense mutation in exon 13 not described  
  grnbmde357a 7bp deletion in exon 5 normal [383] 
  grnbmde360 9bp insertion.13bp deletion in exon 5 normal [383] 
  grnbmde369 5bp insertion in exon 5 norma [383] 
  grnb MO 
(various) 
reduction assessed by RT PCR reduced motor neuron axon length [390, 451] 
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CLN12 Atp13a2 atp13a2sa1158 essential splice site for exon 15 not described  
  atp13a2sa3236 nonsense mutation in exon 24 not described  
  atip13a2sa6735 essential splice site for exon 29 not described  
  atp13a2sa14250 nonsense mutation in exon 20 not described  
  atp13a2sa18624 nonsense mutation in exon 22 not described  
  atp13a2 MO affects splicing small eyes and head at 2 dpf, reduced activity at 
7dpf 
[405] 
CLN13 Ctsf ctsfsa17667 essential splice site for exon 1 not described  
  ctsfsa22423 essential splice site for exon 10 not described  
  ctsfsa28260 nonsense mutation in exon 1 not described  
  ctsfsa35632 nonsense mutation in exon 8 not described  
  ctsfsa42345 essential splice site mutation for exon 12 not described  
CLN14 Kctd7 kctd7hg34 5bp deletion in exon 1 not described [452] 
  kctd7hg35 4bp insertion in exon 1 not described [452] 
  kctd7sa6178 nonsense mutation in exon 2 not described  
  kctd7sa16727 essential splice site for exon 2 not described  
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Table 4. Drosophila homologues of human NCL genes, available models and known associated phenotypes. 




Molecular defect Phenotype Journal articles 
 












Overexpression under Gal4 control 
Accumulation of autofluorescent deposits in the 
CNS, reduced lifespan. 
Altered vesicle dynamics at synapses. 
 
Disruption of the eye modified by regulators of 






CLN2/TPP1  No 
homologue 
    











Deletion of 5’ half of locus 
 
 
Overexpression under Gal4 control 
Overexpression under Gal4 control 
 
 
Knock-in gene fusion 
Hypersensitivity to oxidative stress; under 
development of neurons at the neuromuscular 
junction. 
 
Genetic interactions with Notch and JNK 
signalling pathways; Oxidative stress in the eye 
suppressed by increasing ROS scavenging 
 
Glia expression in the CNS; strong expression in 

















and RNAi lines 
available 
Various deletions, insertions, point 
mutations 
Temperature sensitive locomotor defects, spasms, 
paralysis, progressive neurodegeneration. 











    
CLN7/MFSD8 CG8596 YFP-Cln7 
RNAi lines 
available 
Knock-in gene fusion Expression in glia in the CNS; in the neurons in 
the visual system; localisation to the post-synaptic 




    
CLN10/CTSD CathD cathD1 
RNAi lines 
available 
Deletion of 70% of the coding sequence Autofluorescent accumulation in the CNS, 
vacuolation in the retina; no effect on lifespan. 





    







 Knockdown causes age-dependent storage 
material accumulates in neurons. 
[406] 




 Not studied  
CLN14 No 
homologue 







Table 5. C. elegans homologues of human NCL genes, available models and known associated phenotypes. 
Human protein C. elegans gene Gene manipulation Molecular defect Phenotypes reported 
CLN1/PPT1 ppt-1 gk131 Δ20-100; V insertion at 100  Increased locomotion and maximum lifespan [130]  
  gk134 Δ33-169; frame shift from 160 Decreased body length and locomotion on agar [130] [130]  
  gk139  Δ84-200 Mitochondrial abnormalities and developmental delay [129] 
  gk140  Deletion of exons 2-3 Developmental delay [129] 
  RNAi Reduced expression Decreased median lifespan [130] 
CLN2/TPP1 No homologue    
CLN3 cln-3.1 pk479 Complete ORF deletion Decreased lifespan [221] 
 cln-3.2 gk41 Deletion in promoter + exons 1-2 Decreased fecundity [221]  
 cln-3.3 gk118 Deletion of exons 5-7  
  pk479; gk41;gk118 Triple deletion mutant 
Decreased fecundity + lifespan [221, 222]; increased mitochondria 
[222] 
CLN4/DNAJC5 dnj-14 ok237 Deletion of promoter + ORF 
Short lifespan [253, 259], progressive sensory neuron degeneration 
[253] 
  tm3223 Δ106-214 
Short lifespan [253, 259], progressive sensorimotor dysfunction [253, 
259] 
  RNAi Reduced expression Short lifespan, progressive motor dysfunction [253]  
CLN5 No homologue    
CLN6 No homologue    






W05E10.1    
CLN8 No homologue    
CLN10/CTSD asp-4 ok2693 Deletion of exons 5-6  
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  RNAi Reduced expression Increased [351] or decreased [349, 350] neuronal cell death 
  Plasmid  Overexpression Decreased [351] or increased [349, 350] neuronal cell death 
CLN11/GRN pgrn-1 tm985 Deletion of promoter + exon 1 Altered apoptosis [391]; stress resistance [392]; TDP-43 [393, 394]   
  Plasmid  Overexpression Granulins increase toxicity of TDP-43 [394]  
CLN12/ATP13A2 catc-6 ok3473 Δ280 AAs + frame shift  Slow growth, locomotion defect, reduced fecundity [407] 
  RNAi Reduced expression Reduced dopaminergic neurodegeneration [408]  
  Plasmid  Overexpression Exacerbated dopaminergic neurodegeneration [408]  
CLN13/CTSF tag-196 ok822 Deletion of promoter + exons 1-3  
  ok823 Deletion of exons 1-3  
  ok824 Deletion of exons 2-4  
  tm612 Deletion of exons 4-5  










dictyBase ID Localization in Dictyostelium Processes modulated in Dictyostelium 
PPT1/CLN1 Ppt1 DDB0233890 
Extracellular space [77] 
Macropinocytic pathway [80] 
Phagocytosis [131] 
TPP1/CLN2 
Tpp1A DDB0234303 Lysosome [164] 
Autophagy [164] 
Pre-spore cell differentiation [164] 
Timing of mid-stage development [164] 
Tpp1B DDB0306176 
Golgi complex [165] 
Extracellular space [77, 78] 
Macropinocytic pathway [80] 
Not known 
Tpp1C DDB0185020 Macropinocytic pathway [80] Response to bacterial pathogens [431] 
Tpp1D DDB0309140 Not known Not known 
Tpp1E DDB0304592 Not known Not known 
Tpp1F DDB0214912 
Golgi complex [165] 
Endoplasmic reticulum [165] 
V-ATPase-positive vesicles [165] 
Extracellular space [77, 78] 
Macropinocytic pathway [80] 
Not known 
CLN3 Cln3 DDB0233983 
Contractile vacuole system [223, 224] 
Endocytic pathway [223, 224] 
Golgi complex [78] 
Macropinocytic pathway [80] 
Cell proliferation [223] 
Cytokinesis [225] 
Pinocytosis [223] 
Endo-lysosomal pH [226] 
Osmoregulation [225] 
Protein secretion [223, 224] 
Nitric oxide homeostasis [226] 
Cell adhesion [224] 




Timing of mid-stage development [223] 
Timing of late-stage development [223] 
Spore integrity [225] 
Response to bacterial pathogens [431] 
DNAJC5/CLN4 




Macropinocytic pathway [80] 
Phagocytosis [262] 
CLN5 Cln5 DDB0234077 
Endoplasmic reticulum [283] 
Cell cortex [235] 
Contractile vacuole system [235] 
Extracellular space [235, 283] 
Macropinocytic pathway [80] 
Autophagy [235] 
Cell adhesion [235] 
MFSD8/CLN7 Mfsd8 DDB0307149 Macropinocytic pathway [80] Not known 
CTSD/CLN10 CtsD DDB0215012 
Endocytic pathway (e.g., phagosome, 
lysosome) [352-354] 
Extracellular space [78] 
Macropinocytic pathway [80] 
Bacterial killing [357] 
Cell death [359, 360] 
Timing of early-stage development [354] 
PGRN/CLN11 Grn DDB0238428 Not known Not known 
ATP13A2/CLN12 Kil2 DDB0237611 
Phagosomal membrane [409] 
Macropinocytic pathway [80] 
Bacterial killing [409, 410] 
Predation on yeast [414] 
CTSF/CLN13 
CprA DDB0201647 Extracellular space [78] Osmoregulation [426] 
CprB DDB0214998 Extracellular space [78] Phagocytosis [131] 
DDB_G0291191 DDB0252831 
Endocytic vesicles [430] 
Extracellular space [77, 78] 
Macropinocytic pathway [80] 
Response to bacterial pathogens [431] 
KCTD7/CLN14 
Kctd9 DDB0231824 Not known Not known 
DDB_G0269760 DDB0238663 Not known Not known 
DDB_G0285861 DDB0346929 Macropinocytic pathway [80] Not known 
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